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ANTIMICROBIAL STEWARDSHIP IN THE NEONATAL POPULATION  
Jennifer Duchon, MDCM, MPH 
 
 Antimicrobials are the most frequently used medications in the Neonatal Intensive Care 
Unit (NICU). Antimicrobial Stewardship (AMS) efforts may be used to mitigate the 
consequences of antimicrobial overuse while optimizing clinical outcomes through the safe, 
judicious use of antimicrobials. One target of AMS efforts is to reduce the incidence of 
necrotizing enterocolitis (NEC), a serious intestinal infection in neonates of which a necessary 
component is dysbiosis, the development of aberrant intestinal microbiota typically associated 
with prior antibiotic use. The goal of this ILE is to implement and enhance AMS efforts in the 
neonatal population with a focus on preventing NEC. The specific aims progress through three 
relevant, practical examples of AMS in a stepwise manner.  
 
Methods: In Aim 1, a systematic review of the literature evaluating the relationship between 
antimicrobial therapy and subsequent development of NEC and a meta-analysis including non-
interventional studies was performed. Data were pooled on adjusted odds ratios (OR) and 
analyzed using the generic inverse variance method. All analyses were random effects models. A 
sensitivity analysis was performed based on a range (0-40%) of credibility ceilings.  
In Aim 2, institutional guidelines for early and late onset neonatal sepsis using the principles of 
AMS and the evidence for safe restriction of antimicrobials targeted for reduction in use in 




In Aim 3, a reproducible 2-class latent variable model to extract a date-stamped diagnosis of 
NEC from the Pediatric Health Information System (PHIS) database was created as a tool to 
enhance research evaluating antibiotic use and NEC from large databases. This model was 
created using a subset of infants at two PHIS sites that were able to be validated. M plus software 
was used. 
 
Conclusions: For Aim 1, 36 studies met inclusion criteria for the systematic review, with 33 
proceeding to quantitative analysis. There were 10 RCTs, the remaining being observational 
studies. Using the ROBINS-I or RoB 2.0 tools as appropriate, all studies including the RCTs had 
a least a moderate or high risk of bias respectively. The overall analysis failed to provide 
evidence of an association between prior antimicrobial use and NEC when all 33 studies were 
included, with a summary OR of 1.13, CI95 (0.88, 1.45) and significant heterogeneity, I
2 = 77%.  
Multiple subgroup analyses were performed: “intent” of antibiotic use (prophylaxis versus not) 
drug delivery method (oral versus parenteral) and study type.  
Subgroup analysis of prophylactic enteral antibiotics showed a reduction in NEC: OR 0.2 CI95 
(0.08, 0.54), I2 = 35% while prior use of parental antibiotics showed a positive association with 
NEC OR 1.48, CI95 (1.18, 1.86), I
2 72%; for this subgroup, using a c% shows heterogeneity first 
reaching an estimate of 0% at a ceiling of 10% with nominal statistical significance is maintained 
starting at a ceiling of 10%. This shows that consideration of the biologic mechanism of the 
exposure-disease association, as indicated by the subgroup analyses in this study, must be 
considered when performing further dataset evaluations lest biased conclusions will be reached. 




• The evaluation and management of infants ≥ 35weeks gestational age at risk for 
early onset sepsis at Tufts Medical Center 
• The evaluation and management of infants ≥ 36weeks gestational age at risk for 
early onset sepsis at BronxCare Hospital Center 
 
• The evaluation and management of infants < 36weeks gestational age at risk for 
early onset sepsis at BronxCare Hospital Center 
 
• The evaluation and management of infants at risk for late onset sepsis at 
BronxCare Hospital Center 
 
For Aim 3 a model was successfully created that can be used to add an important layer of detail, 
time-of -event, to patient level variables in a large data set. This model can also be used to 
tabulate the sensitivity of a disease in the absence of a gold standard. The model is portable and 
could serve as a template for the PHIS or other large databases where certain important 
exposures may not be date stamped. The model may be adapted to not only allow for appropriate 
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1.1 Scope of the problem 
Antimicrobials are the most frequently prescribed medications in the neonatal intensive 
care unit (NICU), with some North American centers reporting >95% of extremely low 
birthweight (ELBW) infants having exposure to at least one antimicrobial during their 
hospitalization [1, 2].  The adverse consequences of antimicrobial exposure in the neonate are 
similar to those of older persons, such as colonization and infection with antimicrobial resistant 
organisms (AROs), which have been labelled by the World Health Organization as a global 
health threat [3], as well as dysbiosis, the development of aberrant intestinal microbiota.  
In the United States a recent survey of NICUs in the Neonatal Research Network (NRN) of the 
National Institute of Child Health and Human Development (NICHD) and of the Premiere 
Health Database revealed that up to 83% of Escherichia coli isolates were resistant to ampicillin  
[4, 5], the most common beta-lactam antimicrobial used to treat neonatal early onset sepsis and 
up to 23% were resistant to aminoglycosides. Those same surveys revealed that 7.8-10% of E. 
coli isolates were resistant to both ampicillin and gentamicin, the initial regimen which is 
recommended by the American Academy of Pediatrics (AAP) for EOS [6]. Although the 
concepts, aims and tools described in this  ILE were  developed for use in the United States 
NICU population, similar disturbing trends of early onset neonatal sepsis (EOS) with organisms 
resistant to all first-line agents are already apparent in regions such as the Indian subcontinent 
and sub-Saharan Africa [7-10]. This has led to empiric therapy with broader spectrum 
antimicrobials, further expanding resistance patterns, especially in nations where stewardship 




infections and for AROs due to physiologic considerations as well as the difficulties of drug 
development and approval for neonates, antimicrobial misuse has led to the loss of an increasing 
amount of safe and efficacious drugs to treat this immunocompromised population.   
Dysbiosis in neonates has both short- and long-term sequelae. In older children and adults, 
dysbiosis can lead to a life threatening, highly infectious colitis with the bacterium Clostridium 
difficile. Although neonates are not susceptible to this, dysbiosis in the neonate can lead to a 
condition called necrotizing enterocolitis (NEC) as well as increase the risk of other infections 
due to colonization with virulent hospital-acquired flora[11] [12]. The neonatal period is a 
special time in that the origins of childhood and subsequently adult disease are seeded: 
epigenetic data may now implicate dysbiosis in adverse outcomes such as childhood obesity and 
asthma [13-15] 
Thus, efforts to control antimicrobial exposure through the effort of antimicrobial stewardship 
(AMS) in the neonatal population are of major public health importance.   
1.2 Antimicrobial Stewardship 
 The goal of AMS is to mitigate the consequences of antimicrobial overuse while 
optimizing clinical outcomes through the safe, judicious use of antimicrobials. This includes 
expert guidance on optimal regimen, duration, route and overall need for therapy. Limiting 
antimicrobial use through appropriate stewardship efforts is a major mechanism to prevent both 
short and long term adverse neonatal outcomes [16]. 
Antimicrobial stewardship presents unique challenges in the neonate; both EOS, defined as 
perinatally acquired infection manifesting in the first 7 days of life, and late onset sepsis (LOS) 
which occurs after that time are leading causes of death in infants, with mortality up to 50% in 




Confirmation of sepsis, especially in the smallest infants who are most at risk of both the 
consequences of infection and the consequences of antimicrobial use proves a challenging aspect 
to AMS efforts in the NICU. Classically, neonatal sepsis is defined by one or more positive 
clinical cultures, but historically neonatal blood cultures have been considered poorly sensitive 
due to low bacterial counts and the small volumes of blood that can be obtained from infants. 
The smallest and youngest infants at highest risk for infection also display normal physiologic 
immaturity that overlaps with symptoms of sepsis, making the exclusion of sepsis as a diagnosis 
in many clinical scenarios very difficult.   Antimicrobials are not infrequently administered to 
neonates prior to or without obtaining cultures given the grave consequences of untreated 
infection and the difficulty of blood and spinal fluid sampling from small babies; this absence of 
data further impedes a provider’s ability to limit antibiotic use. 
The use of antimicrobials for suspected infection in the absence of positive cultures, either due to 
lack of samples or mistrust of clinical cultures, is called “culture negative” or “clinical” sepsis; 
Cantey et al have shown that NICU antimicrobial use for culture negative sepsis surpasses that 
for treatment of culture-positive infections [18] [19, 20]. Treatment of culture negative sepsis 
poses a stubborn challenge to AMS efforts, as without a discrete focus of infection, decisions 
about empiric therapy and duration of therapy are often made based on colonization status (i.e., 
urine or tracheal cultures), unit specific ARO prevalence, markers of inflammation, and/or 
clinician uncertainty. Antibiotic use for culture negative sepsis is a key driver of unnecessarily 
broad and protracted therapy that can have adverse consequences for both individual patients and 
for the microbiome of the NICU without clear benefit  [19-21]. 
Table 1 shows some AMS strategies common to both pediatric and adult inpatient medicine, 




Some of these strategies are seen in other subspecialties that treat severely ill or immune 
compromised hosts such as bone marrow transplant services and pediatric intensive care units.  
Table 1: AMS Strategies and Challenges in the NICU 
AMS Strategy AMS Intervention Example Neonatal challenge 
Prescriber audit and feedback Review vancomycin prescription 
with AMS team within 48 hours 
Serial providers (ie, call 
structure) may limit individual 
audit and feedback 
Formulary restriction and prior 
authorization 
Require prior authorization from 
the AMS team before the use of 
meropenem 
Fewer approved drugs for use in 
neonates, especially for AROs  
Education Provide lecture series about 
stewardship principles and 
antimicrobial options for the 
treatment of gram-negative 
pathogens 
Highly specialized field 
precludes neonatologists having 
a strong background in 
microbiology 
Guidelines and clinical 
pathways 
Clinical pathway for antimicrobial 
selection in late onset sepsis 
Considered an imposition on 
clinical judgement 
Dose optimization Vancomycin target trough Rapidly changing PK/PD 
parameters based on post-
menstrual age and renal 
function 
Computer surveillance and 
decision support 
Automatic stop orders after pre-
specified number of doses of 
antimicrobials 
Physician over-ride due to 
perception about small volume 
blood cultures and indolent 
organisms as true pathogens 
 
Despite the challenges, a framework for neonatal stewardship interventions is possible. The 
Vermont Oxford Network, a national network of NICUs collaborating with the goal of sharing 
data and implementing Quality Improvement and benchmarking, have created an educational 
module describing potentially better practices to improve AMS in neonates, of which creation of 
practice guidelines is a key element [3, 22-24]. AMS efforts are becoming more of a target for 




Healthcare Safety Network (NHSN) is now voluntarily soliciting data on antimicrobial use in 
NICUs.  
1.3 The Association Between Prolonged and Prior Antimicrobial Use and Necrotizing 
Enterocolitis 
 
 Necrotizing enterocolitis (NEC) is an intestinal inflammatory condition characterized by 
severe local and systemic inflammation and bowel necrosis. NEC has no cure, and it strikes 
preterm infants very suddenly as they are in the convalescent phase of prematurity [25]. 
Dysbiosis is felt to be a necessary component cause of NEC [12, 26]. There is no treatment for 
this disease, and so prevention is key. Mitigating dysbiosis through control of antibiotic use is 
one of the most important strategies to combat NEC and is the focus of my ILE.  
1.3.1 Necrotizing Enterocolitis 
NEC occurs in approximately 5% of all infants admitted to NICUs, with an incidence 
in the NICHD database of 9% infants who are born at 22-29 weeks gestational age. There is a 
wide range of disease incidence between hospitals in North America, with individual NICUs 
reporting up to a 20% incidence [27-29]. Prematurity is the primary risk factor for this 
disease, and preterm infants bear most of the disease burden, comprising 70% to 90% of total 
NEC cases. Term or near term infants with underlying abnormalities of the intestine, pre-
,peri- and/or post-natal compromise of intestinal blood flow such as those relating to 
maternal vasoactive drug use or structural congenital heart lesions are also at risk [30, 31]. 
The estimated mortality of NEC is 20-50%, likely reflecting heterogeneity in both disease 
process and institutional practices [27, 28]. Up to 60% of infants who survive NEC have 
subsequent morbidities such as intestinal obstruction from stricture formation, intestinal 
failure from loss of intestine due to necrosis, and growth failure. Up to 80% of NEC 




effects of prematurity [32-34]. Infants who require surgical intervention for their disease can 
accrue up to $600,000 in attributable healthcare costs, as well as lifetime costs which extend 
well beyond the neonatal period [35, 36]. Despite decreases in other morbid conditions of 
prematurity such as chronic lung disease, the incidence and outcomes of NEC have remained 
relatively unchanged over the past 30 years [27].  
The etiology of NEC is speculated to be a combination of intrinsic host, pre and post-natal 
exposures. Unifying theories of NEC etiology posit that the consequences of in-utero 
exposure to an inflammatory state such as maternal pre-eclampsia, placental insufficiency or 
infection will cause injury to developing intestinal mucosa (Figure 1)[37]. An abnormal 
inflammatory response also occurs both in the local environment of the gut and systemically 
due to prematurity. Post-natal hypoxia or poor perfusion occurs from neonatal conditions 
such as apnea of prematurity or a patent ductus arteriosus. Bovine versus human milk 
feedings, selective pressure from environmental pressure and exposure to antimicrobials lead 
to colonization of vulnerable intestinal mucosa by pathogenic bacteria, aided by immature 
intestinal immunity [38-42]. NEC also lends itself well to Rothman’s classic causal pie 
model [43]; there are multiple sufficient causes of NEC consisting of the component causes 





Figure 1: Pathogenesis of necrotizing enterocolitis (adapted from Lin and Stoll [37]) 
 
1.3.2. Antimicrobial Use and NEC 
Antimicrobials are used to treat NEC; historically this is because the disease has a 
clinical presentation that is consistent with infection and is associated with bacteremia in 
approximately 15-25% of cases [44-46]; “clusters” of NEC have also been documented [47-
49]. Historically, consistent with the belief that NEC was a primarily an infectious disease, 
oral antimicrobials were used as prophylaxis against NEC in preterm neonates. There were 
several small but randomized controlled trials of oral antimicrobial prophylaxis that showed a 
moderate reduction in NEC in the experimental group [50-55]. The practice of oral 




developed, especially in enteric gram-negative bacteria. These observations led researchers to 
hypothesize that dysbiosis of the GI tract is important to the development of NEC.  
Pre-clinical and Translational Data on Antimicrobial Use and NEC: The link between 
altered intestinal microbiota and the development of NEC is now well supported by 
microbiologic data; both pre-clinical and human translational studies using genomic 
sequencing techniques such as 16s RNA have shown differential stool composition in infants 
near the time of NEC, with a predominance of proteobacteria such as Enterobacter species 
and E. coli as well as an overall decrease in bacterial diversity [12, 41, 42, 56-59]. 
Longitudinal data looking at stool have also shown a relationship between days of 
antimicrobial usage and decreased bacterial diversity [60, 61].  In the studies that examined 
the effect of administration of mother’s own breastmilk, enteral feeding with breastmilk 
appeared to mitigate antimicrobial induced dysbiosis [62]. 
Clinical Studies on Antimicrobial Use and NEC: A sentinel multicenter retrospective 
cohort study on prior and “prolonged” antimicrobial use as a risk factor for preterm NEC was 
published in 2009 using data from the NRN [63]. The presumption that “prolonged” 
antimicrobial use creates dysbiosis, which in turn is a necessary component cause of preterm 
NEC was novel to clinicians at the time, and several non-interventional studies were then 
published [64-66]. Although translational and pre-clinical studies confirmed preceding 
dysbiosis, paradoxically some clinical investigations, the majority being observational 
studies, showed conflicting results when examining prior antimicrobial use and the risk of 
NEC [67-69]. 
One explanation for the lack of consistent effect in these studies reflects the biologic 




intestine by selecting for an unfavorable balance between commensal and pathogenic 
bacteria, the effect of exposure may take weeks to develop. It can be hypothesized that the 
biologically active ingredient, pathogenic bacteria, had yet to bloom in the subjects’ life 
course. This is especially true in studies where there was short follow up time or recent 
antibiotic use relative to the time the subjects were studied, as the intestine is relatively sterile 
immediately after antibiotic administration. In this scenario, antibiotic use will appear to 
reduce the incidence of NEC.  
Another explanation is common biases intrinsic to observational studies, and a lack of 
appropriate study methodology to accommodate these. For example, the sentinel NRN study, 
which used data from 1998-2001 [63], showed an increased incidence of NEC or death, but 
not NEC alone. The same NRN data with the same institutions, but data from 2008-14, and 
did not show an increased odds of NEC or death or NEC alone. Notably, the incidence of the 
primary exposure variable decreased from 53% in the initial study [63] to a nadir of 35% in 
2014 [68]. As well, other co-variables that may influence dysbiosis, such as use of breastmilk 
(Figure 1) may have changed over time, but are unmeasurable in these databases 
1.4. Antimicrobial Stewardship as a Preventative Tool Against NEC  
Necrotizing enterocolitis has no cure, so preventing dysbiosis by controlling 
antimicrobial use is a logical way to reduce or eliminate NEC. AMS efforts should focus on 
reduction of total antimicrobial exposure, as well as limit exposure to specific agents known to 
select for organisms that participate in a systemic and intestinal inflammatory cascade. Both 
reduction in antimicrobial days of therapy and reducing broad spectrum antibiotic use are 
considered “low hanging fruit” in AMS programs, and reducing the incidence of NEC, which 




1.5 Challenges Studying NEC, and the Association Between NEC and Prior Antimicrobial 
Use 
The ultimate goal of evaluating the association between prior antibiotic use and NEC is 
improve patient care by manipulation a modifiable risk factor for the disease; in this case, 
antibiotic use. For the researcher to assess this relationship and for the clinician to appropriately 
diagnose and treat the patient, an unbiased view of the exposure-disease relationship is needed. 
There are several limitations that introduce bias and will hamper the study of a causal 
relationship when studying antibiotic use and NEC. 
Diagnosis of NEC: NEC displays heterogeneity of presentation, from mild disease that may be 
subclinical to fulminant disease that may kill infants in a matter of hours. This intrinsic 
heterogeneity leads to difficulty in diagnosis. To complicate matters further, there is no gold 
standard diagnostic tool or test for NEC. Two primary systems are used to classify NEC, 
however. The first and still most widely used was developed in 1978 by Bell et al and presented 
a system for the uniform clinical staging of neonates already diagnosed with NEC (Appendix A) 
[70]. Over time, these criteria have been augmented, and the Modified Bell’s criteria are a 
continuum of clinical, radiographic and laboratory data [71, 72]. In 2012, the NHSN also 
developed diagnostic criteria for NEC (Appendix A) [3]. Although both systems incorporate 
radiographic findings, the NHSN requires a specific finding called pneumatosis intestinalis. 
However, this finding is often difficult to differentiate from non-pathologic findings on x-rays, 
even in the hands of experienced radiologists. Typically, NEC is over-diagnosed, as the 
immediate consequences of missing the disease are graver than treating. This would lead to bias 
towards the null in evaluating risk factors, as milder disease or misclassification entirely would 




Violations of The Stable-Unit-Treatment-Value Assumption (SUTVA): SUTVA, as 
described by Rubin, has two assumptions: that there are no different versions of treatment, and 
that the potential outcomes of a subject do not vary with the treatments assigned to another 
subject [73].  Lack of clarity in the definition of the exposure and so-called “spillover effects” 
that are not accounted for will lead to a biased effect measure in any analysis undertaken. 
Treatment Variation: With the exception perhaps of stringent non-human experimental 
data, the relationship between antimicrobial use and NEC intrinsically violates SUTVA. The 
variables used as “antimicrobial days” in large clinical studies can mean 1 dose of an 
antimicrobial on 1 day or 3 doses of 3 antimicrobials on a single day. Additionally, class of 
antimicrobial may strongly influence dysbiosis by selective pressure[74, 75], but this may not 
be captured when just counting antibiotic days or doses. 
Interference: The intestinal microbiome of hospitalized NICU patients is also influenced by 
the surrounding ecology of the hospital environment: one expert has stated that “every time 
we provide prolonged antibiotics to one infant, we expose every infant in the nursery to a 
small increased risk of… infection” [76]. Institutional antimicrobial practices heavily 
influence the flora of the unit, which are then acquired by the community of infants.  In 
RCTs of administration of oral probiotics, strains of the experimental product are routinely 
found in the stool of control infants [77-79]. Another phenomenon which provide one 
explanation of “outbreaks” on NEC may be diagnostic bias, where a diagnosis of NEC is 
given to an infant with equivocal radiographic findings due to catastrophic recent disease of 





Conceptualization of The Exposure Disease-Relationship: A change in the intestinal 
microbiome mediated by antimicrobial exposure takes several weeks to develop. However, in the 
initial days after antimicrobial administration the intestine may be relatively sterile; my previous 
pilot work showed a different NEC “risk” at different time points from antibiotic exposure (data 
not shown). As such, the relationship between antimicrobial use and the development of NEC is 
not a monotonic relationship: in the initial days following exposure, antimicrobials may have no 
effect or be negatively associated with the development of NEC; after some time, antimicrobials 
are then positively associated with the development of NEC.  Prior published analyses have 
neither addressed nor accommodated this time dependent and non-monotonic relationship. As 
well, the incidence of the exposure, antibiotic use, and covariables such as enteral feeding can 
change over the course of a study. Misspecification of the model for these relationships, and/or 
failing to account for time dependent variables will lead to bias in the results of any analysis 
performed. 
 
Practical considerations: Few large databases exist that contain neonatal data, and those that do 
often lack elements that are necessary to appropriately model an exposure-disease relationship.  
For example, many “big” databases typically incorporate billing codes for specific diagnoses, 
which are then used as outcomes measures. Billing codes are not “date-stamped,” so the 
assessment of the temporal relationship between exposures such as use of antimicrobials and 
other medications and the diagnosis of NEC cannot be easily explored. These practical 
challenges limit a researcher’s ability to adequately validate the diagnosis of the exposure. This 
will also affect generalizability if available databases with high quality data are limited to private 





1.6. Focus of the Integrated Learning Experience (ILE)  
This ILE summarizes my work to implement and enhance AMS efforts in the neonatal 
population with a focus on preventing NEC. The specific aims progress through three relevant, 
practical examples of AMS in a stepwise manner. 
First, a systemic review and meta-analysis exploring the association between antibiotic use and 
NEC examines the biases in publications on this topic, with a goal of helping clinicians approach 
this problem realizing the limitations of the literature used in bedside decision-making. This aim 
also proposes re-framing the perspective used in the review and meta-analysis to reflect the 
biologically plausible mechanism of the exposure-disease relationship, ie incorporating proposed 
effect of antibiotics on the microbiome. The second aim provides practicable, adaptable clinical 
guidelines for judicious use of antimicrobials for neonatal sepsis. The last aim provides a 
mechanism for researchers to appropriately model the relationship between antibiotic use and 












2. Specific Aims of the ILE 
Specific Aim 1. To systematically review the literature that has evaluated the relationship 
between antimicrobial therapy and subsequent development of necrotizing enterocolitis, and 
perform a meta-analysis including non-interventional studies. A credibility ceiling (c%) was used 
to explore the robustness of the findings. 
 
Specific Aim 2: To create institutional guidelines for early and late onset neonatal sepsis using 
the principles of antimicrobial stewardship and the evidence for safe restriction of antimicrobials 
targeted for reduction in use in neonates by the National Healthcare Safety Network (NHSN). 
 
Specific Aim 3: To create a reproducible 2-class latent variable model to extract a date-stamped 





3. ILE Work Products  
3.1 Aim 1:  A Systematic Review and Meta-analysis of the Literature Assessing 




The association between antimicrobial use and the development of NEC cannot be easily 
tested under the conditions of a typical randomized controlled trial, as ethics preclude 
withholding therapy in a population for whom placebo may increase the risk of death. 
However, as described above, biologic plausibility exists for the association between prior 
antimicrobial use and NEC, with the mediator being dysbiosis of the intestinal microbiome. 
A retrospective study in 2009 using the NRN cohort which showed a reduction in an 
aggregate outcome that included NEC and death [63], and brought this topic to the forefront 
of clinical attention. Other observational studies followed, some with equivocal or conflicting 
results, including a subsequent analysis of data from the same cohort [68].  Years earlier, 
small RCTs had shown a moderate reduction in NEC with oral agents that targeted gram-
negative bacteria [50-55], but prophylaxis fell out of favor due to concerns of antimicrobial 
resistance; institutional memory seemed to discount those earlier studies as more pre-clinical 
and translational data supported the hypothesis of dysbiosis due to antimicrobial use leading 
to NEC [56, 57, 59, 60]. 
This review focuses on two important but poorly recognized reasons for the disparity 
between the biologic plausibility of dysbiosis as a necessary cause of NEC and the lack of 
confirmation by clinical studies: 
Bias: Confounding by indication in observational studies is a particularly unaddressed form 
of bias in the literature on this subject. For example, infants who had other component causes 




antimicrobials, be that duration, broader class, number of antimicrobials administered or 
actual dose of an antimicrobial. The reason for this higher dose was due to the perception that 
the infant was at higher risk of NEC due to these episodes; ie, that the increased dose was 
due to a component causes. 
Errors in the conceptualization of the relationship of antimicrobial use, dysbiosis and 
NEC. Dysbiosis after antimicrobial administration may take weeks to develop. During a 
course of antimicrobials and in the initial days after antimicrobial administration the intestine 
may be relatively sterile; enteral antimicrobials may decrease the bacterial burden much more 
than intravenous antimicrobials due to their local effect.  And so, the relationship between 
antimicrobial use and the development of NEC is not a monotonic relationship: in the initial 
days following exposure, antimicrobials may have no effect or be negatively associated with 
the development of NEC; after some time, antimicrobials are then positively associated with 
the development of NEC.  This effect may be different with enteral versus parenteral 
antibiotics. This time-dependent relationship aligns with earlier studies on prophylaxis, 
where infants were older and less likely to remain admitted to develop dysbiosis and NEC. 
3.1.2 Framework 
This systematic review included observational studies, cohort, case control studies and 
interventional studies reporting on antimicrobial exposure with a comparison group and 
assessing a temporal relationship with NEC.  
The population in the studies evaluated was limited to neonates and infants less than 1 year 





The primary intervention of interest in the studies evaluated was any treatment with a 
parenteral or enteral antimicrobial for any indication prior to the onset of NEC. 
Antimicrobials given for the purpose of treating NEC were excluded. Studies with exposures 
limited to antifungal or antiviral therapy were omitted. For comparison, the majority of 
studies addressed the issue of antimicrobial use prior to NEC by categorizing the exposure as 
“yes/no,” creating a categorical variable for “prolonged duration” of therapy or by regression 
on days of therapy. As well, most studies report multivariable analysis. 
The primary outcome was any diagnosis of NEC; this was typically Bell’s Stage II or greater 
or NEC fulfilling the NHSN definition of NEC. These notably different study designs, 
exposure and disease measures were purposefully included to explore and explain biases as 
opposed to providing a final effect measure. 
The full systematic review and meta-analysis can be found in Appendix B. 
 
3.1.3 Analytic Approach 
Search Strategy The standard search strategy of the Cochrane Neonatal Review group 
was used to search the Cochrane Central Register of Controlled Trials (CENTRAL)(1970- 
October 2017),  MEDLINE (1970 to October 2017) and EMBASE (1970 to October 2017). 
Where appropriate, MeSH subject headings of [enterocolitis, Necroti* OR enterocolitis] 
AND [antimicrobials OR antimicrobials] were used. EMBASE controlled vocabulary was 
‘necrotizing enterocolitis’/exp OR ‘necrotising enterocolitis’ OR ‘necrotizing enteritis’/exp 
OR ‘necrotising enteritis’ AND (‘anti-infective agent’/exp OR ‘anti-infective agent’ OR 
‘antimicrobial agent’/exp OR ‘antimicrobial agent’) AND ([newborn]/lim OR [infant]/lim. 




2001-2017 were reviewed via EMBASE. English language publications only were included. 
Studies not taking place in the US were included if they were English language publications, 
as the underlying exposure-disease relationship is felt to be the same.  A reference librarian 
trained in the search strategies was consulted to ensure the validity of the search language. 
The search was repeated in June of 2020 for the years 2016-2020. The search was conducted 
by one reviewer (JD).  
Data Collection and Analysis: The ROBINS-I tool [80] for observational studies or the 
Cochrane Risk of Bias tool, RoB 2.0 [81] for randomized controlled trials was used as 
appropriate.  A table describing the assessment of bias was created. 
Data were pooled on adjusted estimates and the meta-analysis performed by using generic 
inverse variance method. All analyses were random effects models. Odds ratios (OR) were 
reported. Studies reporting continuous data had their effects converted to lnOR using the 
method of Cox and Snell [82]. Summary estimates with 95% confidence interval (CI) were 
calculated. Revman software from the Cochrane Collaboration was used. 
A sensitivity analysis was performed based on a range (0-40%) of credibility ceilings and the 
consistency of the conclusion examined. The meta and metasens packages of R were used for 
the credibility ceiling [83]. 
 
3.1.4 Results 
The search identified 1031 unique articles. Thirty-six studies met inclusion criteria for the 
systematic review, with 33 proceeding to quantitative analysis, with a total of 16440 infants. 




studies, 2 prospective cohort studies, with 4 “pre and post” or otherwise unspecified study 
designs included in the qualitative synthesis.  
As expected, there was heterogeneity in the antimicrobial regimens, dose and duration of 
exposure. Eighteen studies reported antimicrobial use for EOS administered within the first 3 
days of the infant’s life. Additional antimicrobials for late onset sepsis were included in 10 
studies. Indication and/or regimens were not specified in 8 studies. NEC was reported using 
Bell’s staging or the NHSN criteria in 20/33 studies. None of the 6 studies using prophylactic 
antimicrobials, 5 of which were RCTs, defined NEC using Bell’s staging or the NHSN 
criteria, as these studies occurred prior to development of these tools. All observational 
studies had at least a moderate risk of bias. Most studies reported adjusted analysis for 
confounders, but these were disparate and often unique to the center of the study. Bias in 
classification of interventions, primarily by the differing exposure regimens, and bias in 
measurement of outcomes contributed to the moderate to severe risk of bias in the majority 
of studies. All RCTs also had a moderate to severe risk of bias. 
Quantitative analysis failed to provide evidence of an association between prior antimicrobial 
use and NEC when all 33 studies were included, with a summary OR of 1.13, CI95 (0.88, 





Figure 2. Forest Plot with Summary Measures from Studies Reporting Antibiotic Use Prior to NEC. 
The overall analysis failed to provide evidence of an association between prior antimicrobial use and 
NEC when all 33 studies were included, with a summary OR of 1.13, CI95 (0.88, 1.45) and significant 
heterogeneity, I2 = 77% 
 
3.1.4.1  Subgroup Analyses 
 
Given that the purpose of the meta-analysis is to elucidate and explore biases, 
multiple subgroup analyses were performed specifically to address the error in the 
conceptualization of the relationship of antimicrobial use, dysbiosis and NEC. These 
analyses included “intent” of antibiotic use (prophylaxis versus not) drug delivery 
method (oral versus parenteral) and study type. 
Intent of antibiotic use: Prophylactic enteral antimicrobials showed overall significant 
reduction in NEC: OR 0.2 CI95(0.08, 0.54) and acceptable heterogeneity I




Prior antimicrobial use excluding those for prophylaxis against NEC showed a positive 
association with unacceptable heterogeneity (for our purposes > 40%): OR 1.31, CI95 
(1.02, 1.67), I2 = 77%  
Drug delivery method: Enteral antimicrobials prior to NEC showed a consistent 
decrease in the odds of NEC with a summary OR of 0.37, CI95 (0.17, 0.8), I
2 = 70%  
Prior use of parental antimicrobials showed a positive association with NEC, but again 
with significant heterogeneity; OR 1.48, CI95 (1.18, 1.86), I
2 72%.  
Study type: Analysis by study type with sequential elimination of study type by 
perceived risk of bias showed no effect of prior antimicrobials on NEC with a summary 
OR of 1.19, CI95 (0.79, 1.79), I
2 = 75%. Limiting the study to RCTs only showed a 
protective effect against NEC; OR 0.48, CI95 (0.27, 0.85), I
2 51%. Notably, 9 out of 10 
RCTs used enteral antimicrobials. 
 
3.1.4.2 Credibility Ceiling 
 
To help address bias particularly in the observational studies a credibility ceiling 
(c%) was used to perform a sensitivity analysis. The credibility ceiling evaluates the 
assumption that any single observational study cannot provide more than a maximum 
certainty (100-c%) that an effect is in a particular direction and not in the other or null 
and provides a measure of robustness of the meta-analysis to confounding, both measured 
and unmeasured.  
To evaluate an analysis using this measure, the existing within-study variances are 
inflated to leave a c% chance to observe findings in the opposite direction than suggested 




creating a new random variable and calculating the probability that the variable takes 
values on the opposite direction of the observed estimate. If this probability is less the 
chosen “c” then the variance is recalculated. The new study-specific likelihood functions 
with the inflated variances are then synthesized according to inverse variance meta-
analysis methods. This is repeated for a range of c%, and generally span 1-40, in 
increments of 1. The values can be visually represented by plotting both the I2 statistic as 
well as the OR at a particular c% [83, 84].  It should be stressed that the point of the 
credibility ceiling is not to correct the point estimate, or to “yield definitive conclusions,” 
rather it is to explore “skepticism [85].”  
This sensitivity analysis was performed over a range of credibility ceilings (0-40) for the 
overall analysis and the analyses that showed a significantly increased and decreased 
odds of NEC; these are felt to be subject to the most “skepticism” due the high risk of 
bias. For overall use of antimicrobials prior to NEC (OR 1.13, CI95 (0.88, 1.45) I
2 = 77%, 
nominal statistical significance is not reached (Fig. 3a). When the analysis that was 
limited to studies describing prior antimicrobial use excluding those for prophylaxis 
against NEC (OR 1.31, CI 95 (1.02, 1.67), I2 = 77%, nominal statistical significance is 
lost at a ceiling of 18% (Fig. 3b). For the analysis restricted to prior use of parental 
antimicrobials (OR 1.48, CI 95 (1.18, 1.86), I2 72% nominal statistical significance is 
maintained starting at a ceiling of 10% (Fig. 3c). This can be cautiously interpreted that 
with further study, consideration of the biologic mechanism of antimicrobial use and 
NEC must be considered when performing further dataset evaluations.  





Figure 3a.                                              Figure 3b.                                            Figure 3c.
         
Figure 3. OR (y axis) over a range of range of credibility ceilings. (0-40, x-axis) for the overall analysis (Figure 
3a) and the analyses that showed a significantly increased and decreased odds of NEC; these were studies 
reporting antibiotic use prior to NEC excluding those for prophylaxis (Figure 3b) and analysis restricted to 
prior use of parental antimicrobials (Figure 3c). For overall use of antimicrobials prior to NEC (OR 1.13, 
CI95 (0.88, 1.45) I2 = 77%, nominal statistical significance is not reached (Fig. 3a). When the analysis that was 
limited to studies describing prior antimicrobial use excluding those for prophylaxis against NEC (OR 1.31, 
CI 95 (1.02, 1.67), I2 = 77%, nominal statistical significance is lost at a ceiling of 18% (Fig. 3b). For the 
analysis restricted to prior use of parental antimicrobials (OR 1.48, CI 95 (1.18, 1.86), I2 72% nominal 
statistical significance is maintained starting at a ceiling of 10% (Fig. 3c). 
 
3.1.5. Summary 
Since Cotton et al [76] brought the association between antibiotic use and the risk of 
adverse outcomes such as NEC to the forefront in 2009, other researchers have sought to 
replicate those findings, with varied success. What both translational and epidemiologic studies 
have failed to take into account are the inherent difficulties in evaluating the exposure disease 
relationship; as our meta-analysis shows, there is a great deal of heterogeneity in the definition of 
the exposure, “antibiotic use,” and that different modes of delivery of the same medication may 
have the opposite effect on the risk of developing NEC. This epidemiologic phenomenon 
produces effect measures that are in opposition to each other. The credibility ceiling, which has 
been described by Ioannidis as an attempt to translate the position “I will not be convinced by 
more than (100-c)% that there is some effect in this direction, if only one study is available” [83-
86] demonstrates this by showing us that careful examination and definition of the exposure is 




Recognizing this phenomenon allows us to explore the biologic mechanism behind the observed 
heterogeneity and uncertainty described; the majority of the antibiotics that were given 
prophylactically were also given orally. Orally administered antibiotics are likely to have a 
profound direct effect on the microbiome, where the intestine in functionally sterile for the 
period of time that an infant is in the “NEC risk period.”  
Sander Greenland describes meta-analysis of observational studies as a tool for the purpose of 
exploration and exposure of the bias and heterogeneity that exists in a body of literature, as 
opposed to drawing direct conclusions from the aggregate effect measures [87]. This meta-
analysis rationally completes this task, and will help clinicians approach this issue of antibiotic 









AMS efforts in the NICU are important to each admitted infant, to the unit as a whole, 
and to the institution housing the unit. The Vermont Oxford Network “Potentially Better 
Practices to Improve AMS in Neonates” describes 4 key elements, shown in Table 2 [23]. 
Notable is the need for protocols for early and late onset sepsis to help clinicians make 
appropriate antibiotic choices on a day-to-day basis for common conditions.  
Table 2.  Potential Best Practices in Neonatal AMS 
Demonstrate an organizational commitment and promote an organizational culture that 
supports appropriate antibiotic usage (AU) in the NICU as a critical priority 
Develop, test, implement, and continually refine policies and protocols for 
appropriate AU in specific neonatal conditions including suspected early- and late-
onset sepsis, necrotizing enterocolitis, and surgical conditions 
Apply pharmacy-driven interventions designed to assure appropriate antimicrobial 
treatment of newborn infants 
Report regularly on AU and resistance in the NICU to doctors, nurses, and staff 
        Adapted from Dukhovny et al, Pediatrics 2019[23] 
 
In 2014 the CDC developed the standardized antimicrobial administration ratio (SAAR) to 
provide a risk-adjusted benchmark of antimicrobial use. The SAAR is an observed-to-
predicted ratio, in which institutional antimicrobial days are the numerators and predicted 
antimicrobial days are the denominators [88]. SAARs were created to aid in reporting 
antimicrobial usage data to the NHSN, which at present is a voluntary activity.  In 2018, 
neonatal SAARs were introduced, with dominators created using predictive models that 
incorporate hospital and location factors but not patient level data. Presently any hospital that 




specific neonatal SAAR. Table 3 shows the 7 specific antimicrobial categories that presently 
have modeled SAARs [89]. Although reporting of SAARs is voluntary, hospitals certified as 
a Medicare and/or Medicaid hospital providers may be mandated to report these data in the 
future. 
Table 3. Neonatal SAAR Antimicrobial Category 
 
All antibacterial agents 
Vancomycin predominantly used for treatment of late-onset sepsis 
Broad spectrum antibacterial agents predominantly used for hospital-onset 
infections/late onset sepsis 
Third generation Cephalosporins 
Ampicillin predominantly used for treatment of early-onset sepsis 
Aminoglycosides predominantly used for treatment of early-onset and late-onset sepsis 
Fluconazole predominantly used for candidiasis 
 
Using this background information, the goal of Specific Aim 2 was to develop guidelines for 
clinicians to safely reduce total antimicrobial use in all the SAAR categories, with a long-term 
goal of reduction of HAI such as NEC.  These guidelines were created at sequentially at two 
institutions where antimicrobial data was being reported to the NHSN, and who were motived 
for a clinical practice change to reduce neonatal antimicrobial use. The initial EOS protocol at 
Tufts Medical Center was additionally motivated by an anticipated change in the AAP’s 
guidance.  Criteria for these guidelines are that they align with national guidance such as the 
AAPs recommendations on early evaluation of infants at risk for EOS and the Infectious Disease 
Society of America’s guidance for use of prophylactic fluconazole in neonates [90], be supported 
by the highest quality evidence available, and be modifiable to safely fit local institutional 





3.2.2 Analytic Approach for Early Onset Sepsis: General Methodology of Guideline 
Development  
 
Early-onset sepsis is defined as culture-proven blood stream infection and/or meningitis 
that occurs in infants within the first 3 days of life, or within the first 7 days of life for infants 
continuously hospitalized in the NICU. EOS is acquired in the intrapartum period, though 
may present later, and reflects maternal flora such as Group B beta-hemolytic streptococcus 
(GBS) and Escherichia coli [91]. 
Preterm births are associated with preterm labor, premature rupture of membranes, cervical 
incompetence and fetal distress; maternal intraamniotic infection is often the inciting factor 
for these conditions. For this reason, early onset sepsis guidelines were created to be 
stratified by gestational age, ≥ 35 weeks gestational age and < 35 weeks gestational age. The 
risk of sepsis is not easily dichotomized, but these age strata are typical and practical as 
infants < 35 weeks gestation are almost universally admitted to the NICU based on 
gestational age alone. 
To develop these guidelines, I systematically reviewed the relevant peer-reviewed literature; 
the CDC, NICHD, American Academy of Pediatrics (AAP) and the American College of 
Obstetricians and Gynecologists (ACOG) publications for prevention, evaluation and 
treatment of neonatal sepsis were evaluated. Other hospitals’ guidelines that were shared 
voluntarily with the Pediatric Infectious Disease Society’s (PIDS) Listserv were also 
reviewed.   
I then reviewed the CDC’s neonatal SAARs and targeted: (1) reduction in use of all 
antibacterial agents, (2) use of third generation cephalosporins, (3) decrease in overall usage 




recommended as was limiting duration of empiric therapy to 36 hours. Positive cultures in 
infants <7 days old were examined for the 5 years prior and incidence and the resistance 
patterns of gram-negative organisms were noted.  
This portion of the guidelines was developed and piloted at Tufts Medical Center; the nursery 
at Tufts is small (1-4 patients average daily census) and capable of enhanced surveillance and 
level of care due to a high nursing to patient ratio. By doing this, I was able to adjudicate 
safety by reviewing the management of each infant at risk for sepsis as the guidelines were 
being put in place. The guidelines were then adapted to BronxCare, with the core concepts 
remaining the same but with modifications for local epidemiology and patient care 
considerations, such as the policy of universal NICU admission for infants < 36 weeks, as 
opposed to 35 weeks gestational age. 
3.2.2.1 Early Onset Sepsis Guidelines for Infants ≥ 35 Weeks Gestational Age 
3.2.2.1.1 Strategies for Infants at Risk of EOS 
Review of the literature revealed three general strategies for identification, 
evaluation, and treatment [92] of infants in this age group at risk for EOS:  
Categorical risk factor assessment: Risk factor “threshold values” (ie, maternal 
fever yes/no) are used to determine infants who are at heightened risk for EOS. This 
strategy was designed to be congruent with former CDC recommendations put forth 
in 2010 [93, 94]. The CDC publication has since been revoked but are still in use in 
many hospital systems. 
Multivariate risk assessment: An infant’s risk of sepsis is individualized from 
maternal, infant and institutional factors as well as the neonate’s clinical condition 




Calculator”) can be found at https://neonatalsepsiscalculator.kaiserpermanente.org/ . 
This sepsis risk calculator (SRC) was designed based on a sample of > 200,000 
infants in a multicenter effort using a staged approach for initial model creation, 
stratification and subsequent robust safety validation [95] [96] [97, 98]. 
Risk Assessment Primarily based on Newborn Clinical Condition: Well appearing 
infants whose mothers were diagnosed with suspected intraamniotic infection are 
targeted for enhanced clinical observation [99-101]. 
3.2.2.1.2 Clinical equipoise and challenges  
Categorical risk factor assessments such as those put forth by the CDC in 2010 
have been debated since their publication. Notably, historic data, including data from 
prior to the use of intra-partum GBS prophylaxis was used in in the development of 
those recommendations, which may make these types of strategies non-generalizable 
in a more modern era. The advantage of categorical risk factor strategies is that they 
are risk averse, which is appealing in areas with higher incidences of EOS: many 
infants are evaluated for sepsis and treated empirically. An unfortunate secondary 
gain, especially at smaller and lower acuity institutions is the potential increase in 
income from the prolonged admission to the NICU or billing at a higher level of care 
if the infant remains in the nursery. Limitations include a high antimicrobial usage 
rate, with an estimated NNT of 9000 low risk well appearing infants [96] to prevent 1 
case of EOS. The strategy of categorical risk factor assessment ignores the newborn 
clinical status, instead relying on the mother’s obstetrician to provide a diagnosis of 
intrapartum infection. The administration of intrapartum antimicrobials to the mother, 




as such in these assessments. From 2010-2012, there was no concurring statement by 
authoritative bodies such as the AAP, but in 2012 the AAP recommendations also 
suggested a categorical risk factor assessment strategy [94] [76, 102] [103]. 
Categorical risk factor analyses are no longer part of the CDC’s recommendations as 
of 2019, and the AAP has also modified their recommendations. It may be speculated 
that the neonatal AMS initiatives, including the creation of neonatal SAARs by the 
NHSN helped drive this change.  
Multivariate risk assessments were in part developed in response to categorical risk 
factor recommendations where clinicians felt it was inappropriate to expose well-
appearing infants to potentially prolonged antibiotic use [102]. The advantages of this 
strategy are that information synthesis is based on an individual infant’s risk and 
includes objective data, so very few clinically well infants are treated empirically. 
The primary limitations of multivariate risk assessment strategies are the need for 
ongoing monitoring in a non-ICU setting and a lack of buy-in from stakeholders 
related to beliefs about laboratory data and antibiotic administration to the mother 
prior to delivery. Historically, if a mother was treated with antibiotics for presumed 
intra uterine infection prior to delivery of the infant, it was believed that the infant 
would be “pre-treated,” as medications such as beta-lactams show fetal levels as early 
as 2 hours after administrations [104]. A blood culture drawn near the time of 
delivery from the infant would then be considered unreliable. Many providers 
therefore relied on blood counts and/or inflammatory makers, which have poor 
predictive value for neonatal EOS[92, 103, 105] [106-108]. In contrast, modern blood 




reliable. There are now systems which require a smaller volume of blood, are 
sensitive to a much lower colony forming unit bacterial counts, and contain antibiotic 
neutralizing beads that scavenge free beta-lactam and aminoglycosides that may be in 
neonatal blood from maternal administration [109]. The most widely used and well 
validated multivariate risk assessment tool recommends no screening labs except a 
blood culture above a certain prior probability of sepsis [96, 97]. This created a 
conflict where providers are asked to make a paradigm shift about what was 
historically perceived as the “truth” (blood counts/ inflammatory markers) and is now 
considered subjective, versus what was perceived as unreliable (blood cultures) but is 
now the “truth.” This strategy is one of the most well studied risk assessments 
however [98]. Puopolo et al evaluated a stepwise integration of the “Kaiser sepsis 
tool” using a time series analysis to compare sepsis evaluations and antimicrobial 
administration pre and post implementation of guidelines using the risk assessment 
tool in a multicenter study.  In this analysis the incidence of  blood culture sampling 
decreased from 14.5% to 4.9% (adjusted difference, −7.7%; 95% CI, −13.1% to 
−2.4%) and empiric antimicrobial use decreased from 5.0% to 2.6% (adjusted 
difference, −1.8; 95% CI, −2.4% to −1.3%)[97]. 
Risk assessment primarily based on newborn clinical condition has the advantage 
that very few infants are evaluated or empirically treated for sepsis. This option relies 
on serial examinations and enhanced monitoring, which present a challenge for most 
nurseries due to variability in the expertise and skill of providers able and available to 
do these exams around the clock. The AAP stresses that the “identification of initially 




an anticipated outcome of this approach, [92, 99];  obviously this is not acceptable to 
many institutions. And again, there is a potential loss of income generated from 
NICU admission and medication administration.  
3.2.2.2 Early Onset Sepsis Guidelines for Infants < 35 Weeks Gestational Age 
Few evidence-based recommendations are available for the evaluation of sepsis in 
infants < 35 weeks gestational age.  Many premature infants will have some respiratory 
or systemic instability as an expected part of physiologic immaturity, so risk stratification 
tools used for term infants cannot be applied to preterm infants. A diagnosis of EOS is 
also difficult to establish using laboratory tests, as patterns of blood count indices and 
markers of inflammation overlap between EOS and conditions that affect the fetus such 
as placental insufficiency.  
Preterm births are associated with preterm labor, premature rupture of membranes, 
cervical incompetence and/or fetal distress; intraamniotic infection is often the inciting 
factor for these conditions. The CDC national incidence of EOS at 0.5 cases per 1000 
infants in born at ≥37 weeks’ gestation can be compared with 1 case per 1000 infants 
born at 34 to 36 weeks’ gestation, 6 cases per 1000 infants born at <34 weeks’ gestation, 
20 cases per 1000 infants born at <29 weeks’ gestation, and 32 cases per 1000 infants 
born at 22 to 24 weeks’ gestation [110].  The circumstances of birth are the most 
commonly used clinical variables used to determine risk of sepsis in preterm infants 
[110-113]; to date two multicenter trials have been undertaken to stratify infants into 





3.2.3 Analytic approach for Late Onset Sepsis: General Methodology of Guideline 
Development  
Late-onset sepsis (LOS) is defined as culture confirmed blood stream, urinary 
infection (UTI), meningitis, skin and soft tissue infection (SSTI), NEC or pneumonia that 
occurs in infants after the first 7 days of life for infants continuously hospitalized in the 
NICU [91, 116]. This reflects the microbiologic fingerprint of the NICU, as well as acquired 
host factors such as indwelling devices, colonization with AROs and medication history.  
Birthweight is a strong predictor of LOS; among infants < 750 g birth weight, the cumulative 
incidence of LOS is >40% [117-119]. Objective assessment of risk is often confounded by 
the overlap in signs of LOS versus expected preterm physiologic behavior such as respiratory 
instability, apnea and feeding intolerance. Lack of data-driven guidelines for empiric 
antimicrobial choice often means that initial choice is driven by local expert custom and may 
have a high degree of inter-and intra-provider variability.  Even in the case of confirmed 
disease, duration and choice of therapy are not well delineated for neonates. 
I reviewed the available peer-reviewed literature as was done for EOS, but there were no 
national guidelines published on this topic. Local guidelines shared voluntarily with the PIDS 
by the respective institution were reviewed. 
I again reviewed the CDC’s neonatal SAARs, and targeted: (1) reduction in all antibacterial 
agents, (2) use of third generation cephalosporins, (3) decrease in overall usage in 
aminoglycosides, (4) reduction in use of vancomycin and (5) broad spectrum antibacterial 
agents predominantly used for LOS, such as piperacillin/tazobactam. I recommended limiting 




All positive blood, urine and tracheal cultures associated with the NICU were examined. 
Special attention was paid to and the incidence and species of fungal, pseudomonal species 
and S. aureus species.  In addition to guidelines for evaluation and empiric therapy, working 
definitions of specific infections for which there is diagnostic ambiguity in the neonate were 
developed. 
The NICU at Tufts had few infants in the highest risk strata for LOS (i.e, <750g), and few 
overall incidences of LOS. There was a long-standing practice of restrained LOS sepsis 
evaluations and targeted as opposed to empiric vancomycin, third generation cephalosporin 
or broad-spectrum antibiotic use. As such, the guidelines, including antimicrobial 
management for LOS were tailored for BronxCare, and based on the low prevalence of 
MRSA and high prevalence of pseudomonal species in the BronxCare NICU. 
3.2.3.1 Controversies in Diagnosis and Therapy for LOS 
 
Diagnosis: There is no validated diagnosis for neonatal UTI, VAP (the preferred term 
for ventilator associated events in neonates) or meningitis in the absence of a positive 
spinal fluid culture.  
Choice of Therapy: Guidelines may be modified for local epidemiology; for example, 
units with a high prevalence of Pseudomonas species or multidrug resistant gram-
negative organisms may start with a higher-level aminoglycoside, such as at BronxCare.  
Empiric vancomycin is not recommended except when there is a high suspicion for 
MRSA infection (>10% incidence). Although coagulase negative staphylococci (CONS) 
is the most common pathogen in LOS [118] [119], it rarely causes fulminant disease, and 
no increase in mortality has been shown when empiric oxacillin is instituted in place of 




Fluconazole prophylaxis is consistent with Infectious Disease society of America 
guidelines, but the overall number of patients studied is low  [90, 122]. 
Duration of Therapy: Duration of therapy is the not well validated in infants; although 
trial data do exist on shortening the course of therapy for conditions such as urinary tract 
infections, pneumonia and gram-negative bacteremia in older children[123] [124, 125], 
extrapolation to NICU infants is rarely done. Even for infections such and meningitis, 
organism-specific recommendations are minimally data driven[126]. 
 
3.2.4. Implementation of Guidelines 
Each policy for EOS and/or LOS was evaluated by multiple stakeholders. An initial draft 
of each set of guidelines was first evaluated by pediatric infectious disease physicians from 
both the AMS team and the general inpatient consult team for input on pharmacology and 
local epidemiology, as well as to facilitate buy-in. Guidelines were then presented to NICU 
leadership to review, to assess for palatability and ensure buy in, as the guidelines contained 
changes from previous practices in NICU admission criteria and choice of empiric therapy.  
To have additional input and feedback on the guidelines and in preparation for policy 
implementation, Powerpoint didactic lectures on EOS and LOS were presented to the NICU 
and nursery physician teams, including leadership, attendings and fellows prior to the rollout 
of the guidelines. A lecture on EOS, which policy contained the sharpest fracture from 
previous practice, was presented to the general pediatric department in a grand rounds 
format.  Separate didactics on EOS and LOS were presented to the NICU fellows during their 
core teaching sessions, as they are key in initiating LOS evaluations and therapy in the NICU 




EOS was presented to the pediatric residents, as they would be frontline providers in the 
implementation of the guidelines in the nursery. This lecture was integrated into the core 
NICU/nursery curriculum, which is repeated monthly in order to capture the majority of 
residents as they rotate through the nursery and NICU.  All lectures for faculty and trainees 
were designed to encourage discussion and allow for questions during the lecture, as well as 
questions after. The guidelines themselves as well as the process of using them were taught 
using in-person short lectures as well as Powerpoint lectures for pediatric residents and in-
service type lectures for labor and delivery, mother-baby and NICU nurses. This process was 
piloted at Tufts and repeated at BronxCare, modified for a different nursing structure and 
lack of fellows. Laminated pocket cards for the pediatric residents at Tufts with abbreviated 
EOS guidelines were created.  Guidelines were then published in the appropriate web-based 
hospital guideline forum for each institution. As patients presented and questions arose about 
management, Pediatric Infectious Disease providers and myself were available on-call for 
questions. Bedside re-enforcement of the guidelines with nurses, residents and NICU 
attendings was performed. Short reminder lectures on the concepts of EOS and LOS as 
patients were assessed. 
Figure 4 shows a timeline of the development and implementation of EOS and LOS 
guidelines at Tufts Medical center and BronxCare. 
A representative lecture on the Kaiser Sepsis tool provided to the nursery, NICU and labor 
and delivery nurses as well as a lecture on late onset sepsis and early onset sepsis provided to 





Figure 4: Timeline of development and implementation of EOS and LOS guidelines at Tufts Medical 
Center and BronxCare Hospital System. 
These guidelines were created at sequentially, starting with EOS at Tufts Medical Center. The effort at 
Tufts was prompted by a change in the AAPs guidance on EOS in infants ≥35 weeks; efforts at both 
institutions also motivated by examining local institutional SAARs to find high yield areas of antibiotic 
usage improvement. 
 
3.2.5. Summary of Guidelines 
Four guidelines were created. These are: 
• The evaluation and management of infants ≥ 35weeks gestational age at risk for early 
onset sepsis at Tufts Medical Center 
• The evaluation and management of infants ≥ 36weeks gestational age at risk for early 
onset sepsis at BronxCare Hospital Center 
• The evaluation and management of infants < 36weeks gestational age at risk for early 
onset sepsis at BronxCare Hospital Center 






As described above, EOS guidance for infants ≥35weeks gestational age was created first, 
followed by EOS and LOS guidelines from BronxCare (Figure 4) The strength of 
recommendations (labeled as either “strong” or “weak/conditional”) and the quality of 
evidence (labeled as “high,” “moderate,” “low,” or “very low”) were ascribed according to 
the GRADE approach [90, 127-130]( Figure 5).  
 
 
Figure 5: Schematic of the GRADE recommendations 
Approach to rating the quality of evidence and strength of recommendations of the guidelines using the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. Figure 
adapted from Pappas et al.[90] 
 
In the GRADE system, four factors are considered when deciding on the strength of the 
recommendations; only one of those is the “quality of the available supporting evidence.”  
GRADE recommendations note that other factors, such as the magnitude of the difference 
between the desirable and undesirable consequences, certainty about values and preferences 




recommendations. As well, the equity, acceptability and feasibility of interventions 
considered [129, 130]. As such, the GRADE system does not preclude strong 
recommendations and low evidence. For example, recent IDSA guidelines on the treatment 
of pediatric acute hematogenous osteomyelitis recommend against routine use of direct 
surgical site antimicrobials (strong recommendation and very low certainty of evidence), 
with the caveat that this recommendation favors balancing desirable and undesirable 
consequences [131]. This is certainly applicable to neonatal guidelines, where a harm may be 
well documented (development of antibiotic resistance, dysbiosis) but experimental or large 
cohort data may be lagging. 
Another option offered by the GRADE method is replacing the word “weak” with 
“conditional” (on values, resources available or setting), “discretionary” (at the discretion of 
the patient or practitioner) or “qualified” (with explanation of the circumstances under which 
the recommendations were made)[129]. This may add clarity to the rationale behind the 
grading. Recommendation grading was made by me; the limitations of a single grader is 
acknowledged. As there is no randomized trial data available to inform these 
recommendations, and quality of large cohort studies weighted heavily, as this comprises 
much of the best quality data in neonatal sepsis. As well, the balance between benefits, harms 
and burdens, resources, acceptability and feasibility was privileged when ascribing strength 
of recommendations.  
The guidelines for Tufts were not graded, as the literature at the time was limited and the 
guidelines simplified for a small population. 




For infants ≥ 35weeks gestational age, I used multivariate risk assessments as a 
framework. Under this framework, objective information about the infant, institution and 
intrapartum circumstances are assessed. The recommended risk assessment tool is the 
Kaiser Sepsis Risk Calculator (https://neonatalsepsiscalculator.kaiserpermanente.org )  
[92, 95-97]. This tool can be embedded in an Electronic Medical Record systems such as 
EPIC ©. Guidance can then be offered based on the infant’s prior probability of sepsis, 
and a second stratification of post-natal clinical status can offer further guidance based on 
a new posterior distribution. For infants at Tufts, the posterior distribution based on 
clinical status was used. At BronxCare, only the initial prior probability was used. This 
multivariate risk assessment caries the best recommendation based on the GRADE rating, 
and Kaiser Sepsis Risk Calculator, upon which this recommendation is built, had large 
scale implementation and high quality validation. 
3.2.5.2 Early Onset Sepsis Guidelines for infants <35 weeks Gestational Age 
To create these guidelines, I took into consideration the indication for birth, the 
mode of delivery, and maternal factors such as intraamniotic infection, GBS intrapartum 
prophylaxis, rupture of membranes and the clinical status of the infant, and created 
recommendations based on 2 risk strata. 
Infants at highest risk for sepsis are born due to cervical incompetence, preterm labor, 
PROM, IAI, and/or unexplained onset of fetal distress and should be evaluated for sepsis 
and started on empiric antimicrobial therapy. 
Infants at lower risk for sepsis: have indications for delivery that are noninfectious in 
nature, such as maternal hypertensive disease, placental insufficiency, fetal growth or 




amniotic membranes (ROM). Evaluation and empiric treatment for EOS is not 
recommended. 
In all guidelines for EOS, the neonatal SAARs targeted were reduction in use of all 
antibacterial agents, use of third generation cephalosporins, decrease in overall usage in 
ampicillin and aminoglycosides by specifying the narrowest possible agents for empiric 
therapy and recommendations about limitation of duration of empiric therapy to 36 hours.  
I customized the EOS guidelines for infants ≥ 36 weeks gestational age at risk for EOS at 
BronxCare Hospital Center and infants ≥ 35weeks gestational age at risk for early onset 
sepsis at Tufts Medical Center to incorporate the policy of universal NICU admission for 
infants < 36 weeks gestational age at BronxCare. As well, enhanced surveillance and 
level of care at Tufts Medical Center due to a high nursing to patient ratio allows for 
younger infants to be cared for in the “routine well baby” nursery. It also allows infants 
to receive intravenous antimicrobials and more frequent vital sign monitoring than typical 
nurseries. At BronxCare, the practice had been to admit all infants to the NICU and 
prescribe empiric antibiotics regardless of clinical status based on a categorical risk factor 
assessment. To negotiate NICU provider discomfort with a shift in policy and the 
challenges of enhanced monitoring in a large nursery, a more conservative approach 
using the infant’s prior probability of sepsis was used. 
3.2.5.3 Late Onset Sepsis Guidelines 
The goals of the modifiable guidelines for evaluation and empiric treatment of LOS 
infants were to use the most robust definitions of infections possible, provide safe 
recommendations for empiric therapy based on local epidemiology, narrow coverage as 




Recommendations comprised the following: 
• Confirmation of the definition and conditions comprising of LOS, with additional 
working definitions of neonatal urinary tract infection and ventilator associated 
pneumonia 
• Recommendations for the method of blood and urine sampling for culture 
• Empiric therapy with Oxacillin, with recommendations for use of ceftazidime and 
aminoglycosides based on organ system involvement 
• Organism and organ-based recommendations for duration of antibiotic therapy  
 
 
Appendix E comprises full guidelines for: 
• The evaluation and management of infants ≥ 35weeks gestational age at risk for early onset 
sepsis at Tufts Medical Center 
• The evaluation and management of infants ≥ 36weeks gestational age at risk for early onset 
sepsis at BronxCare Hospital Center 
• The evaluation and management of infants < 36weeks gestational age at risk for early onset 
sepsis at BronxCare Hospital Center 







3.3 Aim 3: Create a Reproducible 2-Class Latent Variable Model to Extract a Date-




A sufficient number of cases and a knowledge of the time of the outcome are essential to 
assess the relation between NEC and antibiotic use. Large, multicenter non-proprietary 
databases may have the former, but lack a date-stamped diagnosis for which a time to event 
or other flexible model can be applied.  
A latent class is a variable indicating underlying groups of classes based on observable 
characteristics. Membership in a class is said to be “latent” because it cannot be directly 
observed. Latent class models (LCM) relate a set of observed variables to a set of latent 
variables, whereby a class is characterized by a pattern of conditional probabilities that 
indicate the chance that variables take on certain values. Latent class analysis (LCA) is used 
to find classes in multivariate categorical data. In typical LCA, a “scale” is formed from a set 
of items assumed to be reflective measures of the latent variable; scores on items in the scale 
are driven by the latent construct, and analysis seeks to reconstruct the number of latent 
classes that are underlying this structure. In our case, we reverse this assumption: the items 
(exposures) are formative of the latent variable. We presume then that true disease status can 
be considered as a dichotomous latent variable with only two classes/categories, diseased and 
not diseased, and that any correlation between the exposures will be totally explained by 
these two classes. Given a set of observed predictors (i.e., clinical signs, symptoms, lab tests) 
associated with disease but assumed to be conditionally independent of each other, a 2-class 
LCA model can be fit and yield estimates of the prevalence of the disease and the conditional 




This model is especially useful in our case, where a variable that cannot be directly extracted, 
ie, “NEC at a specific time X,” can be extracted by using a set of variables that can be 
observed and are associated with the latent variable of interest.  This analytic technique was 
used to create a 2-class LCM to predict and subsequently extract the index latent variable, a 
diagnosis of NEC in the Pediatric Health Information System (PHIS) dataset at a specific 
point in time during the infant’s hospital admission.  This model follows the framework 
shown if Figure 6. 
 
 
Figure 6: Schematic of a Formative 2-Class Latent Class Model 
Schematic diagram of a 2-class LCM, where the Composite Factors represent NEC (yes or no), and Y1-
Y6 represent predictor variables, zeta the error term. Adapted from Jarvis, Mackenzie and Podsakoff 
[135]. 
 
3.3.2 Analytic Approach 
The PHIS dataset is an administrative database that collects information from 49 free-
standing children’s hospitals in North America that are members of the Children’s Hospital 
Association. It is comprised of individual level patient data in the form of International 
Classification of Diseases, 9th and 10th Revision-Clinical Modification (ICD-9-CM and 




for radiologic and laboratory tests, medications, procedures and supplies that are charged to 
the patient. Diagnosis codes are not date stamped [136]. 
 3.3.2.1 Method of Model Creation 
 Data was requested from patients admitted between January 1, 2009 and December 
31, 2019 who had a NICU admission within 2 days of birth, an ICD-9 or -10 code 
associated with NEC stage II, III, or not otherwise specified (NOS) and who were <33 
weeks gestational age and/or less than 1750 grams at birth were included to capture the 
most certain diagnosis of NEC. Three observed variables with overlapping time periods 
and with a known time point in the patient’s hospitalization were used to form the latent 
variable. These variables were: 
1. Receipt of broad-spectrum therapy (defined as any antibiotic EXCEPT 
monotherapy with cefazolin, oxacillin, nafcillin, vancomycin, penicillin, 
ampicillin, clindamycin, gentamicin, tobramycin, or amikacin) for ≥5 calendar 
days in duration AND 
2. Radiographs containing the abdomen performed for ≥3 consecutive days during 
antibiotic course AND 
3. Receipt of ≥3 consecutive days of total parenteral nutrition 
 
3.3.3 Results 
I adjudicated the exposure variables and diagnosis of NEC in patients from 2 sites 
(Columbia Presbyterian and Cornell Medical Center) within PHIS using manual chart review 
of the medical records of infants with an ICD-9 or 10 diagnosis of NEC (N=163). It was 
manually validated that all the infants who had an ICD-9 or 10 diagnosis of NEC did indeed 




who died within 5 days of their diagnosis (N=2). An LCA was run in the “M plus” statistical 
modeling program. The 3 mandatory exposure items were modelled in a 2-class analysis. The 
new latent variable that was created indicates class membership in “NEC at a specific time 
X.”  
This model was a success by technical standards; the new latent variable that was created 
accurately reflected the date of diagnosis of NEC in the PHIS data set; however, this was not 
unexpected as all the patients had the same response pattern except those infants that died; as 
such, the probabilities of belonging to the latent class “NEC at a specific time X” is very 
high. The Mplus code and output is shown in Appendix F. 
3.3.3.1 Challenges in Creation of a 2-Class Latent Variable Model for NEC  
 First, the diagnosis of NEC in the PHIS is indicated by ICD-9 or -10 codes, and 
the LCA model was created using this variable. However, the diagnosis of NEC in the 
database may not reflect that the infant actually had NEC; using the NHSN criteria 
59/163 (36%) infants had a diagnosis reportable to the CDC as NEC. We can speculate 
that the individuals who generate codes from the medical record may not know how to 
classify NEC. Infants who were coded as “NEC NOS” were a heterogeneous group who 
may have undergone an evaluation for NEC with the disease being ruled out. Other 
gastrointestinal syndromes overlap in some signs and symptoms and may be mis-coded. 
These issues are not unique to PHIS and are a source of misclassification bias that may 
occur in any study that uses “large data.” This is where an LSV could also be quite 
useful; discriminating a diagnosis of NEC in the PHIS database versus the “truth.” The 
LSV model thus far has only been done on a diagnosis of NEC per the database. An LSV 




would be reconstructed into a 2-class “True NEC Yes/No” or a 3-class No NEC/Mild 
NEC/Surgical or Severe NEC latent variable. 
Adequate sample size is not well defined for LCA models; in general, each latent class 
should have > 5 members. Based on recent estimates of the PHIS dataset, we estimate 
that it contains approximately 300,000 neonates < 90 days admitted to the NICU and 
approximately 4000 infants with ICD-9 or -10 diagnosis codes for NEC given the years 
used.  There may be correlation between exposures that is not explained solely by 
disease, for example infant may receive TPN and antibiotics for many other kinds of 
infections. This leads to a lower “quality” of the items. Ideally, for each person we want 
probability of class membership to be large for one of the classes and small for all the 
rest, suggesting clear classification into one and only one class. Lower quality items 
make the probability of class membership more difficult to discern, making a larger 
sample size a necessity.   
A more substantial issue is the lack of a validated diagnosis of NEC. NEC is a 
heterogeneous condition, and the final common clinical entity represents an “umbrella” 
or “potpourri” diagnosis, likely encompassing several different diseases and representing 
differing etiologies [25, 137, 138]. NEC in preterm infants who develop devastating 
“NEC totalis,” involving necrosis of > 80% the intestine likely have different causal 
pathways to disease than those infants with indolent NEC.  Kim et. al elegantly describe 
these challenges in terms of aligning the need of researchers to define NEC in order to 
strengthen their understanding of risk factors and pathogenesis with the need of clinicians 
to appropriately treat the patient in front of them [139]. In the end, the diagnosis of NEC 




to biased studies. This would make the results of the analysis uninterpretable; for 
example if one form of NEC antibiotics prevents NEC and in another disease antibiotics 
“cause” NEC, the resulting effect measure will reflect the dominant disease, or may 





















4. Strategy to Move Forward 
Antimicrobial stewardship is a challenging endeavor, as the goal is to change practices 
that are often deeply engrained in exchange for long term gains that may not be immediately 
apparent to the clinician, especially an intensive care physician. The clinician must weigh the 
potential benefits to a single patient against the potential risks to the patient and public health 
impact of antimicrobial prescribing.  Many practices surrounding antibiotic use in the neonate, 
like other aspects of critical care medicine, are geared towards preventing imminent catastrophic 
consequences in a vulnerable population where inappropriate assumptions could cause death. 
The classic randomized controlled trial is focused on the “giving of things:” it is exceedingly 
hard to perform a trial in which the active intervention is placebo or a diminution of an 
intervention such as a narrow spectrum antibiotic. In the case of antimicrobials, their negative 
effect is not immediately apparent and as the exposure-disease relationship is not monotonic; 
antimicrobials reduce the risk of NEC for a short time before causing harm. Every clinician 
wants this “safe” time to be when they are taking care of the patient.  
The intention of my ILE work is to educate clinicians to the biases present in the way we think 
about antibiotics and their consequences, as demonstrated by Aim 1. In Aim 2 I have developed 
clear, consistent yet modifiable guidance that will safely and positively change antibiotic use in 
the NICU; the validation measures that are described below give the clinician a measurable 
outcome that may be benchmarked. In Aim 3 I provide the tools to inform research on the 
consequences of antibiotic use in the neonate using large national databases in a robust and 
adaptable manner. 
In the next sections I describe next steps and actions that will be taken to fully implement and 




4.1.  Specific Aim 1. A Systematic Review and Meta-analysis of the Literature Assessing 
Antimicrobial Exposure and NEC Incorporating a Credibility Ceiling  
 
Systematic reviews and meta-analysis are not static and are designed to have the search 
repeated every 1-2 years, or as new data emerge. This body of work will be updated and then 
submitted for review to Paediatric and Perinatal Epidemiology. The credibility ceiling will 
be re-performed with new data. Again, this meta-analysis is designed to elucidate and 
engender discussion about the biases intrinsic to the exposure disease relationship and the 
individual studies, not to provide a “true” effect measure.  
4.2 Specific Aim 2: Guidelines for Early and Late Onset Neonatal Sepsis Using the 
Principles of Antimicrobial Stewardship 
 
The next important stage of this project is the validation phase, incorporating 
measures of safety and reduction in target SAARs. 
4.2.1. Validation of Sepsis Guidelines  
The impact of guidelines is evaluated by changes in practice (process measures) 
and changes in patient condition (outcome measures). At the same time, the safety of 
these guidelines should be monitored by ensuring that no balancing measures such as 
“bug-drug mismatch,” increases in death, or end stage complications such as metastatic 
infection occur.  
Process measures:  Antibiotic usage at the unit level over time is one appropriate 
process measure. Neonatal SAARs have the advantage of being a consistent measurement 
of antibiotic usage over time within an institution. If antibiotic use is reported to the 
NHSN, an institution is then provided with their SAAR. This is accurate, as usage data 
are reported directly from a platform such as an electronic medication administration 




calculated in a transparent manner and may be biased, especially towards smaller 
institutions with higher risk patient populations such as those found in medically 
underserved areas.   
Also impactful are examining sepsis evaluations. This has been used as part of validation 
studies for the broad scale implementation of the “Kaiser Sepsis Calculator”  [97, 98].  
Sepsis evaluations not only inform length of stay but also parental satisfaction, as infants 
must undergo painful, often serial blood sampling, and may be separated from the parents 
for treatment.  
Outcome measures: The ultimate desired outcome of these guidelines is a decrease in 
adverse consequences such as LOS, NEC or unit prevalence of antibiotic resistant 
organisms without a concurrent increase in adverse outcomes such as culture proven EOS 
or attributable mortality.  Measuring these outcomes is challenging since they are rare; 
for example, a very large center that does 5000 deliveries annually will have an expected 
EOS case number of 1-2 per year.  
There is a higher incidence of late onset sepsis, but lack of standardization of outcome 
definitions (i.e., ventilator associated pneumonia) in neonates contributes to biased 
measurements. As well, the multifactorial nature of LOS may confound this outcome 
measure. Colonization and infection with antibiotic resistant organisms are also 
multifactorial and challenging to study if guidelines are studied in isolation.    
Measuring the long-term sequelae of infection such as neurodevelopmental impairment is 
generally not feasible when dealing with single center data. Long term outcomes are also 
challenging to study without significant resources to capture, retain and serially evaluate 




Table 4 summarizes the metrics that will be used to validate these guidelines.  
Table 4. Validation of Sepsis Guidelines 1 
Metric EOS ≥ 35 weeks GA EOS < 35 weeks GA LOS 
 
Adherencea + + + 
    
Evaluations performedb + + + 
    
SAAR    
           All antibacterial agents + + + 
           Vancomycin for LOS   + 
             Broad spectrum 
antibacterial  
             agents for LOS 
+ + + 
             Third generation 
Cephalosporins 
+ + + 
             Ampicillin for EOS + +  
             Aminoglycoside Use + + + 
              Fluconazole Use   + 
    
Standardized incidence ratiosc    
             Positive blood culture + + + 
             Positive CSF culture + + + 
             Attributable Mortality + + + 
             Re-admission +   
             NEC  + + 
    
Bug/Drug Mismatchd + + + 
 
 
Validation will be performed at BronxCare. The validation parameters will be presented 
in PowerPoint format to the Division of Neonatology and AMS Committee quarterly, but 
feedback on adherence, evaluations and bug/drug mismatch will be provided monthly to 
the NICU team at one of their weekly faculty meetings. 
Adherence to all sets of guidelines will be tracked. Adherence will be measured as: 
 
1 aAdherence will be measured as % of sepsis evaluations using recommended antibiotic regimens and % of EOS 
evaluations in infants ≥ 35 weeks GA following guideline recommendations. bEvaluations performed per 1000 
admissions. cStandarized incidence ration will be calculated using the data from 2015-2020 as expected, after assessing 





o % of sepsis evaluations using guideline recommended antibiotic regimens (ie, 
oxacillin versus vancomycin) 
o % of EOS evaluations in infants ≥ 35 weeks GA following guideline 
recommendations 
Sepsis evaluations for EOS and LOS per 1000 admission will be tracked. BronxCare 
reports neonatal antibiotic usage voluntarily to the NHSN, making neonatal SAARs a 
convenient and relevant metric to track over time (Table 4). Standardized incidence ratios 
will be calculated for NEC, positive blood and CSF cultures, mortality due to sepsis and 
re-admissions for infection  
Comparator data will incorporate the previous 5-year average incidence of each condition 
for the respective quarter. Bug-drug mismatch will be tracked.  
 
4.2.2. Challenges in AMS Guideline Implementation 
The sociology of AMS is complex: an ongoing major challenge is the difficulty in 
modifying longstanding, entrenched clinical behaviors to successfully impact a positive 
change in practice. Tensions exist between bedside clinical providers and those who they 
perceived to be in “cognitive subspecialties,” where the urgency of treating an ill patient 
may not factor in as intimate a way into decision making. This was also a notable issue 
during the COVID pandemic with general medication stewardship [140]. One accepted 
methodology is so-called “handshake stewardship,” where members of the AMS team 
engage the clinical team daily, typically during bedside rounds [141]. This allows the 




team to provide relevant teaching moments and see the practical challenges of treating 
patients. This also provides a more balanced power dynamic between the clinician and 
the AMS team, so that the bedside providers feel their authority is respected [142].  
The implementation of these guidelines was not as challenging as is typical; both 
institutions were ready to make changes; the recent shift in national guidance in treatment 
of EOS away from dogmatic empiric therapy and the looming threat of mandated 
reporting of antimicrobial usage to the NHSN with a desire to improve local SARRs 
made this effort timely. I purposely did not provide guidance regarding the selection of 
infants for whom sepsis evaluations were indicated, apart from EOS in infants ≥ 35 
weeks. This allows neonatologists to retain clinical autonomy in their area of expertise, 
the evaluation of critically ill infants. The hope is that this will encourage participation in 
all the guidelines, and eventually lead to a culture shift of restrained and judicious 
antibiotic usage. I was in unique positions in both institutions, where I function in official 
capacities in clinical  
neonatology, pediatric infectious diseases and on the AMS teams. This obviously may 
not always be the case in other situations. 
4.3 Specific Aim 3: Create a Reproducible 2-Class Latent Variable Model to Extract a 
Date-Stamped Diagnosis of NEC from The Pediatric Health Information System (PHIS) 
Database 
 
The model is simple and has so far been run on a very limited portion of the PHIS 
database that had the diagnosis of NEC and the mandatory exposure variables validated. The 
next step, planned in collaboration with colleagues at Lurie Children’s Hospital, Chicago IL, is 




the model with increasingly larger portions of the dataset. Once the model is validated, the final 
goal is to perform a time-to event analysis using the PHIS cohort and the date-stamped diagnosis 
of NEC. This model is portable; for example, the relationship between blood transfusions and 
NEC within 48 hours of exposure has been proposed. The model can also be used with other 





5. Reflection on the ILE 
My work in the field of neonatal antimicrobial stewardship highlights the adverse 
consequences of antimicrobial overuse in infants, specifically as it relates to NEC. I have 
evaluated the literature, performed an analysis, and described biases in a meta-analysis of studies 
on prior antimicrobial use and NEC. I have developed guidelines for appropriate use of 
antimicrobials for neonatal sepsis which have been adopted by Tufts Medical Center and 
BronxCare Hospital. I developed a tool to extract a date stamped diagnosis of NEC in non-
proprietary large datasets to enable researchers to study the relationship between antimicrobial 
use and NEC using more flexible models to incorporate time dependent variables.   
When creating the ILE, I identified eight competencies as central to both specific aspects of my 
work as well as the work as a whole. Table 5 links my specific aims with the competencies. 
Aim 1, a systematic review and meta-analysis of the literature assessing antimicrobial exposure 
and NEC, was primarily composed of observational data. This is reflective of the reality of 
neonatal antimicrobial stewardship, as well as the clinical neonatology. As opposed to 
performing a traditional meta-analysis, I had to make it clear to the audience that this was a 
meta-analysis to highlight and explore the biases in the literature, not to produce a summary 
effect. To demonstrate this, I performed multiple analyses using biologically plausible 
subgroups, and I searched for a sophisticated method of explicating biases, such as unmeasured 
confounding, unrecognized mediators, and improper modeling. I ultimately used a credibility 
ceiling, which required a more complex coding for the analysis. 
The strength of my meta-analysis is how it conceptualizes the time varying exposure-disease 
relationship, recognizes the biases of the included studies, and performs the analyses to highlight 




effect measure, it is instead to make the clinician cognizant of the strengths and biases in the data 
used in clinical decision making. The credibility ceiling I incorporated is a method of describing 
this. This method is not designed to cast doubt on the validity of the meta-analysis, rather to 
assess the idea that any single observational study cannot provide more than a particular surety 
that an effect is in a particular direction and not in the other or null, which is a decision made by 
clinicians daily. The primary weakness of this work product is the lack of second reviewer. 
Although I take pains to explicate bias, the lack of a second reviewer leaves this paper prone to 
some of the biases I try to point out to my colleagues. 
Aim 2, the creation of guidelines for early and late onset neonatal sepsis using the principles of 
antimicrobial stewardship required a comprehensive review of the literature on neonatal sepsis 
and the CDC’s NHSN antibiotic usage reporting systems. Much that is written on neonatal sepsis 
is based on single center observational studies and “expert opinion,” with the few quasi-
experimental trials occurring without concurrent control groups. I had to again recognize and 
assess these biased data, and in turn create safe guidelines knowing the limitations of the data. 
My guidelines were implemented in institutions that either had no protocols in place or that 
performed a large number of sepsis evaluations, and/or and initiated treatment with broad 
therapy, and so I was challenged to engage with multiple different services and levels of 
personnel prior to their utilization in an effort to be accepted. The impetus to create and 
implement these guidelines came either from NICU or pediatric leadership and hospital AMS 
efforts; first, standardization of practice has become the norm; for example, all pediatricians 
must show evidence of a “quality improvement” effort to maintain board certification with the 
American Board of Pediatrics. Second, the guidelines were created at a time of general change in 




by the NHSN, and the series of publications about neonatal sepsis calculators [92, 95, 96, 102, 
113]. The challenge was not in actual buy-in for creation of the guidelines by NICU, ID or 
pediatric leadership. The challenge, like any in stewardship, is acceptance and implementation 
by individual providers, both neonatology and infectious diseases.  
My guidelines for diagnosis and management of neonatal sepsis are comprehensive, adaptable, 
and well researched. They highlight my ability to evaluate the evidence, but also my clinical 
experience with the feasibility of best practices in a very vulnerable population. These guidelines 
have buy-in from multiple levels of administrators and clinical experts. They can be easily 
adapted to different institutions with different clinical care structures. 
There are important limitations to this aim; the fundamental data on which they are based are 
observational and not terribly robust; the grading of these guidelines reflects the spectrum of 
available data in neonatal sepsis; I acknowledge that a lack of a panel input to grade them is also 
a limitation.  The present lack of guideline validation by either process measures or outcome 
measures is an important limitation.  Presently the specific guidelines developed for Bronxcare 
are in the implementation phase and have not yet begun validation. The first guideline I 
developed, the Tufts early onset sepsis protocol, I consider a pilot study in my ability to develop 
a document, to engage an interdisciplinary team and implement guidelines from start to finish. 
However, at Tufts it is difficult to evaluate either process measures or outcome measures, as their 
baseline antibiotic utilization rates are low and sepsis events are rare.   
Aim 3, the creation of a model to extract a date-stamped diagnosis of NEC, was informed by 
preliminary work from Aim 1. Although NEC shapes a great deal of the clinical practice of 
neonatology, it is a rare outcome; to study the effect of overuse of antibiotics on NEC requires a 




since patient level data is often not detailed enough for other analysis. I was able to develop a 
model that can be used to add an important layer of detail, time-of -event, to patient level 
variables in a large data set. The model I developed uses a latent variable structure; these models 
can also be used to tabulate the sensitivity of a disease in the absence of a gold standard, which is 
also a key detriment in NEC research. 
My latent variable model is simple but solves a unique problem with respect to the necessity of 
temporality in the exposure disease relationship when using large data sets. It is easily 
implemented, and modifiable code is available in R as well as SAS and Mplus software. This 
model is portable and could serve as a template for the PHIS database where certain important 
exposures may not be date stamped. Its adaptation will not only allow for appropriate extraction 
of variables, but also allow the correct modelling of time-dependent co-variables. 
From a practical standpoint, this model is in the very early phase, and has only been run on a 
single center limited data set. From an internal validity standpoint, NEC is not easily diagnosed; 
added to the errors that are common in multicenter databases such as variability in coding and 
diagnosing disease, and the model may display precision but be of limited use if inaccurate. 
 
Table 5. CEPH competencies addressed in the ILE 
CEPH Competency ILE Specific Aim2 
 
Data & Analysis   
             Design a qualitative, quantitative, mixed methods, policy analysis or 
               evaluation project to address a public health issue 
1,2,3 
              Explain the use and limitations of surveillance systems and national  
              surveys in assessing, monitoring and evaluating policies and 
programs  
              and to address a population’s health 
2 
 
2 1 = Systematic review of the literature and meta-analysis about the relationship between prior antibiotic use and 
the risk of NEC. 2 = Institutional guidelines for antibiotic use in early onset and late onset neonatal sepsis. 3 = 




Leadership, Management & Governance  
             Integrate knowledge, approaches, methods, values and potential  
              contributions from multiple professions and systems in addressing  
              public health problems 
2 
Policy & Programs  
             Propose inter-professional team approaches to improving public 
health 
2 
MSPH Epidemiological Competencies   
           Conduct and interpret the synthesis of evidence-based knowledge 
including  
           systematic reviews and meta-analyses 
1 
           Understand the use of contemporary analytic methods to address issue  
           such as validity, confounding, effect measure modification and 
mediation 
1,3 
           Demonstrate knowledge of data resources essential to epidemiology - 
their  
           advantages & limitations: vital statistics, national and international 
population- 
           based surveys, census data, public use databases 
2,3 
           Develop skills to evaluate epidemiologic research from study design  
           through field implementation to analysis and interpretation 
2,3 
 
Antimicrobial stewardship is a team activity; often the AMS team is led by a non-clinician and 
tensions can arise when guidelines or other measures designed to mitigate the adverse 
consequences of antibiotic use are perceived among the primary patient care team as supplanting 
or minimizing their role. The process of successfully engaging multiple layers of stakeholders, 
from bedside nursing to division heads not only with guidelines but with the rationale behind 
them and both clinical and research strategies to move forward is an ultimate strength of my 
work. 
Aim 1 of my ILE advances the knowledge about the relationship about antibiotic use and NEC in 
an innovative way, and this study should be presented for publication. The search will be 
updated and a second reviewer, preferable a DrPH or MPH student with a clinical background 
will be recruited. The aim is to submit for this work for publication by December of 2021.  
To advance evidence-based practice surrounding antibiotic use in the NICU, which was the focus 




Perinatal Quality Collaborative (NYSPQC) was established with a goal “to prevent and minimize 
harm through the translation of evidence-based guidelines to clinical practice.” Using elements 
from my prior work with NYSPQC during their CLABSI initiative I would propose a statewide 
project through this working group to target the Neonatal SAARs reported to the NHSN. This 
project would help reduce antibiotic use through standardization of practice and creation of 
neonatal stewardship bundles, including guidelines for antibiotic usage that would be developed 
in a multi-center review process. Additional elements to integrate into this project include a 
survey of participants to define core reasons for prolonged antibiotic use in NICUs; this effort 
can inform a cluster randomized trial of these bundles or their components. 
On a national and international level, the Institute for Advanced Clinical Trials for Children (I-
ACT) helps build both practical and intellectual research infrastructure in areas that are 
particularly challenging; they have recently published a white paper on NEC, attempting to 
standardize diagnosis to reduce bias in research of interventions to prevent and treat the disease. 
As a former junior member of this group, I would now request senior membership on their NEC 
subcommittee, where I could have an advisory role in both observational and interventional 
study design. 
NEC is a rare disease with complex relations to many exposures; a sufficient number of cases 
and a knowledge of the time of the outcome are essential to assess the relation between NEC and 
its causes. Once my LSV model is complete and validated, the final goal is to perform a time-to 
event analysis using the PHIS cohort and the date-stamped diagnosis of NEC. This model is 
portable; for example, the relationship between blood transfusions and NEC within 48 hours of 
exposure has been proposed. The model can also be used with other national datasets, such as the 




Glossary of Terms: 
NICU: neonatal intensive care unit 
ELBW: extremely low birthweight infants are <1000 grams at birth 
AMS: antimicrobial stewardship  
EOS: early onset neonatal sepsis; positive blood culture or meningitis occurring before 7 days of 
life. 
ARO: antimicrobial resistant organisms; typically MRSA (methicillin resistant Staphylococcus 
aureus), VRE (vancomycin resistant enterococci), and MDR-GNB (multi-drug resistant gram 
negative bacilli). 
NICHD: National Institutes of Child Health and Human Development, a branch of the NIH 
dedicated to the health of children 
NRN: The Neonatal Research Network; a network of NICUs that are participating in the NICHD 
funded research 
NSHN: National Healthcare Safety Network  
NEC: Necrotizing enterocolitis; an intestinal inflammatory condition characterized by local and 
systemic inflammation and bowel necrosis 
LOS: Late onset neonatal sepsis; positive blood or urine culture, meningitis, skin and soft tissue 
infection or pneumonia occurring after 7 days of life in an infant continually hospitalized  
HAI: Healthcare acquired infection  
SUTVA: Stable-unit-treatment-value assumption  
PHIS: The Pediatric Health Information System  
AAP: American Academy of Pediatrics  




LCM: Latent class models  
SAAR: standardized antimicrobial administration ratio. A risk-adjusted observed-to-predicted 
ratio, in which institutional antimicrobial days are the numerator and predicted antimicrobial 
days are the denominator. Dominators are created using predictive models that incorporate 
hospital and location factors  
 SRC: sepsis risk calculator. The most commonly used and well validated synthetic tool  used to 
estimate an infant’s risk of EOS is the “Kaiser Sepsis Calculator”. This can be found at 
https://neonatalsepsiscalculator.kaiserpermanente.org/ . Further information can also be found in 
Appendix 6 
LCA: Latent class analysis  
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Appendix A: Modified Bell’s Staging for NEC and the NHSN Diagnostic 
Criteria for NEC 
 
Table 1: Modified Bell’s Criteria for NEC [70-72] 
Stage 
Classification of 
NEC Systemic signs Abdominal signs 
Radiographic 
signs 












IB Suspected Same as IA Grossly bloody 
stool 
Same as above 
IIA Definite, mildly ill Same as IA Same as above; 


























cellulitis or mass 
IIIA Advanced, 
severely ill, intact 
bowel 




acidosis, DIC, and 
neutropenia 
Same as above, 














Table 2: NHSN criteria for NEC [3] 
Infant (< 1 year of age) has at least one of the clinical and one of the imaging test findings 







Occult or gross blood in stools 
 
Imaging test finding: 
Pneumatosis intestinalis 






Extensive bowel necrosis (>2 cm of bowel affected) 
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Appendix B: Antibiotic Use in the Early Neonatal Period and Necrotizing 




Background: Administration of antibiotics to preterm infants early in their life course leads to 
an altered intestinal microbiome, which in turn is a necessary cause of necrotizing enterocolitis 
(NEC). This is an incremental process that may not occur immediately after or during antibiotic 
use, and enteral or prophylactic antibiotics may transiently reduce dysbiosis. Comparing 
administration of empiric antibiotics under trial conditions is not feasible in the neonatal 
population.  
Objectives: The purpose of this study was to systematically review the literature about the 
relationship between prior antibiotic use and the risk of NEC and to perform an exploratory 
meta-analysis incorporating a credibility ceiling (c%). 
Data sources: The Cochrane Central Register of Controlled Trials, PUBMED, MEDLINE and 
EMBASE were searched from the years 1970-2019. 
Study selection and data extraction: Observational studies, cohort and case control studies and 
interventional studies with comparison groups were included if antibiotic exposure and a 
temporal relationship with NEC were present. A single reviewer extracted publication journal, 
year of publication, authors, country of study, study design study time frame, sample size, data 





Synthesis: Data were pooled on adjusted odds ratios (OR) and analyzed using the generic 
inverse variance method. All analyses were random effects models. A sensitivity analysis was 
performed based on a range (0-40%) of credibility ceilings. 
Results: A total of 36 studies met inclusion criteria for the systematic review, with 33 and a total 
of 16440 participants proceeding to quantitative analysis. There were 9 case control studies, 10 
randomized controlled trials and 8 retrospective cohort studies, 2 prospective cohort studies, with 
4 “pre and post” or unspecified study designs. There was great heterogeneity in the antibiotic 
regimens used and in the indication the quantification and duration of exposure. All but 1 
observational study had at least a moderate risk of bias. All RCTs also had a moderate to severe 
risk of bias, primarily due to bias in subject selection and/or incomplete reporting of data. 
Overall, the study failed to provide evidence of an association between prior antibiotic use and 
NEC, with a summary OR of 1.13, CI95 (0.88, 1.45) and significant heterogeneity, I
2 = 77%. 
Subgroup analysis of prophylactic enteral antibiotics showed a reduction in NEC: OR 0.2 CI95 
(0.08, 0.54), I2 = 35% while prior use of parental antibiotics showed a positive association with 
NEC OR 1.48, CI95 (1.18, 1.86), I
2 72%; for this subgroup, using a c% shows heterogeneity first 
reaching an estimate of 0% at a ceiling of 10% with nominal statistical significance is maintained 
starting at a ceiling of 10%. 
Conclusion: Reports on the association between prior antibiotic use and NEC display a large 
amount of bias and heterogeneity. Analysis without consideration of the biologic mechanism of 









Necrotizing enterocolitis (NEC) occurs in approximately 5% of infants admitted to neonatal 
intensive care units (NICUs), with an incidence in the National Institutes of Child Health and 
Development (NICHD) database of 9% of infants born at 22-29 weeks gestational age. Unlike 
other morbid conditions of the newborn such as both early and late onset sepsis, neither the 
incidence nor the outcome of the disease has seen significant improvements over time [143] 
[144]. A key component of prevention and treatment of sepsis is the use of broad-spectrum 
antibiotics. However, the consequences of neonatal sepsis if diagnosis is delayed have resulted in 
liberal use of antibiotics, which in turn has led to the treatment of many uninfected infants.  It has 
been noted that the empiric use of antibiotics, although potentially lifesaving, is not without 
consequences to both the individual and the community [75]. In one meta-analysis of 
observational data researchers examined the relationship between adverse neonatal outcomes and 
antibiotic therapy [74]. Studies among primarily retrospective cohorts using multivariable 
logistic regression have reported associations between prolonged exposure to antibiotics in the 
first days of life and an increased odds of developing NEC [63, 64, 145]. This observation has 
led many clinicians to conclude a causal association between antibiotic use and NEC. However, 
data from other cohorts have shown conflicting results, with no change or decreased odds of 
NEC among neonates receiving prior antibiotic therapy, especially those who are late preterm, 
full term, or diagnosed with NEC relatively early in life [69]. Esaiassen et al point out that many 
of the observational studies included in their meta-analysis had limited sample size or were of 
poor to moderate quality [74]. The association between antibiotic use and the development of 




withholding therapy in a population for whom placebo would likely increase the risk of death, 
and so it is key that a thorough exploration of the inherent biases of the available observational 
data be undertaken.  
 
The purpose of this study was to systematically review the literature about the relationship 
between prior antibiotic use and the NEC and to describe the biases present in these data. A 
meta-analysis of observational data was then performed, incorporating a credibility ceiling (c%) 




For this systematic review used PRISMA [146] as well as Meta-Analysis Of Observational 
Studies in Epidemiology (MOOSE) guidelines were incorporated [147]. Both the systematic 
review and meta-analysis have been prospectively registered with PROSPERO 
(CRD42016047265). Following Cochrane procedures, a population, intervention, comparison, 
and outcome (PICO) question was developed: “Among infants at risk for NEC, does prolonged 
antibiotic therapy, compared with no or shortened antibiotic therapy increase the odds of NEC?” 
 
Study Selection 
Observational studies, cohort and case control studies and interventional studies with comparison 
groups reporting on antibiotic exposure and assessing temporal relationship with NEC were 
included. Case reports, case series without a comparative population, letters to editors (not 




references were read to identify additional potential studies. Available conference abstracts from 
the Pediatric Academic Society’s (PAS) and the European Society for Pediatrics (ESP) annual 
meetings were also reviewed. 
 
Study Population 
The study population was limited to neonates and infants less than 1 year of age who were 
admitted as inpatients to an acute care facility. Infants of all gestational ages were included. 
 
Exposure 
The primary exposure of interest was any treatment with a parenteral or enteral antibiotic for any 
indication prior to the onset of NEC. Antibiotics given for the purpose of treating NEC were 
excluded. Studies with exposures limited to antifungal or antiviral therapy were omitted. 
Subgroup analyses were conducted for oral antibiotics given as prophylaxis for NEC, as the 
direction of the relationship is expected to be a protective effect [148]. When multiple exposure 
variables were described in a particular study, privilege was given to the analysis describing 
early antibiotic usage as a categorical variable.  
 
Outcome 
The primary outcome was a diagnosis of NEC Bell’s Stage II or greater or NEC fulfilling the 
Centers for Disease Control and Prevention’s (CDC) National Healthcare and Safety Network 
(NHSN) definition of NEC. Studies with aggregate outcomes that did not report outcome data 






The standard search strategy of the Cochrane Neonatal Review group was used to search the 
Cochrane Central Register of Controlled Trials (CENTRAL)(1970- October 2017),  MEDLINE 
(1970 to October 2017) and EMBASE (1970 to October 2017). Where appropriate, MeSH 
subject headings of [enterocolitis, Necroti* OR enterocolitis] AND [antibiotics OR 
antimicrobials] were used. EMBASE controlled vocabulary was 'necrotizing enterocolitis'/exp 
OR 'necrotising enterocolitis' OR 'necrotizing enteritis'/exp OR 'necrotising enteritis' AND 
('antiinfective agent'/exp OR 'antiinfective agent' OR 'antibiotic agent'/exp OR 'antibiotic agent') 
AND ([newborn]/lim OR [infant]/lim. Abstracts from the PAS annual meeting were reviewed 
from 2001-2017; ESP abstracts from 2001-2017 were reviewed via EMBASE. English language 
publications only were included. A reference librarian trained in the search strategies was 
consulted to ensure the validity of the search language. The search was repeated for the years 
2016-2020. 
The search was conducted by one reviewer (JD). This reviewer is dually trained in neonatology 
and infectious diseases and has a sound knowledge base in evaluation of the relevant literature.  
 
Data collection and analysis 
Criteria and methods to assess the risk of bias and methodological quality of included studies:  
The methodological quality of each study was reviewed and data from eligible reports abstracted. 
The risk of bias among included studies was assessed by each reviewer using the ROBINS-I tool 
for observational studies [149] or the Cochrane Risk of Bias tool, RoB 2.0 [81] for randomized 





Methods used to collect data from the included studies 
The following data were extracted: publication journal, year of publication, authors, country of 
study, study design (i.e., cohort, case-control), study time frame, sample size, unadjusted data on 
exposure and outcome, adjusted effect measure and standard error, and method of outcome 
ascertainment.  
 
Methods used to synthesize data 
The majority of studies addressed the issue of antibiotic use prior to NEC by categorizing 
exposure as “yes/no,” creating a categorical variable for “prolonged duration” of therapy or by 
logistic regression with days of antibiotic therapy as a continuous variable and the subsequent 
report of an odds per day of antibiotic exposure, and were described as such (Table 1).  As well, 
the majority of studies report multivariable analysis, both as a means of exploring additional 
variables as exposures and to control for confounding. A table describing the assessment of bias 
was created. 
Data were then pooled on adjusted estimates and a meta-analysis performed by using generic 
inverse variance method. All analyses were random effects models due to the expected 
heterogeneity inherent to observational studies about NEC. Odds ratios (OR) were reported. 
Studies reporting continuous data had their effects converted to lnOR using the method of Cox 
and Snell [150]. Summary estimates with 95% confidence interval (CI) were calculated.  
To additionally assess for confounding, a sensitivity analysis was performed based on a range (0-
40%) of credibility ceilings and the consistency of the conclusion examined. The credibility 
ceiling evaluates the assumption that any single observational study cannot provide more than a 




and provides a measure of robustness of the meta-analysis to confounding, both measured and 
unmeasured [83].  
Revman from the Cochrane Collaboration was used for meta-analysis and the meta and metasens 
packages of R were used for the credibility ceiling. 
 
Results 
Overview of included studies: 
The search identified 1568 citations, with 1031 unique articles. 768 articles were eliminated after 
title and abstract screen, with 263 screened further. 66 potentially eligible full-text articles were 
retrieved, 36 studies met inclusion criteria for the systematic review, with 33 proceeding to 
quantitative analysis (Figure 1, Table 1 and Table 2). There were 9 case control studies [59, 64, 
69, 151-156], 10 randomized controlled trials [50-53, 55, 157-161] and 8 retrospective cohort 
studies [63, 66, 145, 162-166], 2 prospective cohort studies [167, 168], with 4 “pre and post” 
[54, 169-171] or otherwise unspecified study designs included in the qualitative synthesis. A 
total of 16440 participants were analyzed.  
There was great heterogeneity in the antibiotic regimens used and in the duration of exposure, 
50% of studies reported effect antibiotic use for early onset sepsis (N=18). These regimens 
typically included ampicillin and gentamicin. Antibiotics for late onset sepsis were included in 
10 studies. Indication and/or regimens were not specified in 8 studies (Table 1). Table 2 shows 
studies excluded from the quantitative analysis. 
 




The ROBINS-I tool, in development by the Cochrane collaborative, was used to evaluate the risk 
of bias in observational studies, with the RoB 2.0 tool used for RCTs. All observational studies 
had at least a moderate risk of bias; although the majority of studies reporting adjusted analysis 
for confounders, these were disparate and unique to the center of study. Bias in classification 
interventions, as described above by the disparate antibiotic regimens, and bias in measurement 
of outcomes contributed to the assessment of moderate to severe risk of bias in the majority of 
studies. All RCTs also had a moderate to severe risk of bias, primarily due to bias in subject 
selection and/or incomplete reporting of data (Table 3). 
 
Necrotizing Enterocolitis: 
Data from 33 studies were included in the analysis. (Figure 1). This included unpublished data 
from 1 study, Cantey et al[169]. No conference abstracts were included. Of the 66 papers 
reviewed, 2 studies were excluded after the authors were unable to provide additional data on the 
unique outcome of NEC. Overall, the study failed to provide evidence of an association between 
prior antibiotic use and NEC, with a summary OR of 1.13, CI95 (0.88, 1.45) and significant 
heterogeneity, I2 = 77% (Figure 2). Subgroup analysis was performed based on study type, use of 
enteral antibiotics as prophylaxis against NEC (intent of antibiotic) and route of administration. 
The administration of prophylactic enteral antibiotics showed an overall significant reduction in 
NEC: OR 0.2 CI95(0.08, 0.54) and acceptable heterogeneity I
2 = 35% (Figure 3). When the 
analysis was then limited to studies describing prior antibiotic use excluding those for 
prophylaxis against NEC, again, there was a trend towards evidence of an association between 
prior antibiotic use and NEC, but with unacceptable heterogeneity: OR 1.31, CI95 (1.02, 1.67), I
2 




Given that there may be a difference in the biologic mechanisms of prior antibiotic use and NEC 
given route of administration, and the effect of these exposures may be in opposition to each 
other, further analyses were conducted. The use of enteral antibiotics prior to NEC showed a 
consistent decrease in the odds of NEC with a summary OR of 0.37, CI95 (0.17, 0.8), I
2 = 70% 
(Figure 5), while the prior use of parental antibiotics showed a positive association with NEC, 
but again with significant heterogeneity; OR 1.48, CI95 (1.18, 1.86), I
2 72% (Figure 6). Studies 
were included in the enteral group if the use of any enteral antibiotics were described.  Studies 
were included in the parental group if the no use of enteral antibiotics was described, or the study 
took place exclusively in the US, Canada or the Middle East if antibiotic regimes were not 
described. 
Analysis by study type, with sequential elimination of study type by perceived risk of bias 
showed no effect of prior antibiotics on NEC with a summary OR of 1.19, CI95 (0.79, 1.79), I
2 = 
75% (Figure 7), while limiting the study to RCTs only showed a protective effect of NEC; OR 
0.48, CI95 (0.27, 0.85), I
2 51% (Figure 8). 
 
Credibility Ceiling: 
Figures 9, 10 and 11 show a sensitivity analysis over a range of credibility ceilings (0-40) for the 
overall analysis and the analyses that showed a significantly increased odds of NEC. For overall 
use of antibiotics prior to NEC (OR 1.13, CI95 [0.88, 1.45] I
2 = 77%, Figure 2) heterogeneity first 
reaches an estimate of 0% at a ceiling of 11% (Fig. 9a), and as expected, nominal statistical 
significance is not reached (Fig. 9b). When the analysis that was limited to studies describing 
prior antibiotic use excluding those for prophylaxis against NEC (OR 1.31, CI95 (1.02, 1.67), I
2 = 
77%, Figure 4) heterogeneity first reaches an estimate of 0% at a ceiling of 12% (Fig. 10a); 




prior use of parental antibiotics (OR 1.48, CI95 (1.18, 1.86), I
2 72%, Figure 6) heterogeneity first 
reaches an estimate of 0% at a ceiling of 10% (Fig. 11a); nominal statistical significance is 
maintained starting at a ceiling of 10% (Fig. 11b). 
 
Discussion 
Since Cotton et al [63] brought the association between antibiotic use and the risk of adverse 
outcomes such as NEC to the forefront in 2009, other researchers have sought to replicate those 
findings, with varied success. In the decade since Cotton et al published their work, the biologic 
mechanism behind the plausibility of this has been demonstrated to be dybiosis, or the effect that 
antimicrobials have on the developing and uniquely vulnerable neonatal microbiome. What both 
translational and epidemiologic studies have failed to take into account are the inherent 
difficulties in evaluating the exposure disease relationship; as our meta-analysis shows, there is a 
great deal of heterogeneity in the definition of the exposure, “antibiotic use,” and that different 
modes of delivery of the same medication may have the opposite effect on the risk of developing 
NEC. This epidemiologic phenomenon produces effect measures that are in opposition to each 
other. The credibility ceiling, which has been described by Ioannidis as an attempt to  translate 
the position “I will not be convinced by more than (100-c)% that there is some effect in this 
direction, if only one study is available” [83-86] demonstrates this by showing us that careful 
examination and definition of the exposure is extremely important to explore the exposure 
disease relationship. 
We can then explore the biologic mechanism behind the observed heterogeneity and uncertainty 
described; the majority of the antibiotics that were given prophylactically were also given orally. 




where the intestine in functionally sterile for the period of time that an infant is in the “NEC risk 
period.” Without dysbiosis, which can be considered a “necessary” cause, NEC does not occur 
[26, 43]. It is also notable that the majority of RCTs were designed to evaluate prophylactic oral 
antibiotics to prevent NEC. The practice of administering oral antibiotics as prophylaxis against 
NEC ultimately fell out of favor in the majority of centers, as dysbiosis is ultimately not 
prevented, merely delayed, and colonization with drug-resistant organisms from selective 
antimicrobial pressure may then ensue. Although the majority of the cohort and case control 
studies were correct in their assumptions of the biologic mechanism of disease, the majority were 
simply unable to assess such important variables as time from drug administration to NEC, 
cumulative drug dose, mode of administration and external modifiers of the microbiome, 
including enteral feeding practices, which are all important variables in the relationship between 
antibiotics and dysbiosis. 
Sander Greenland describes meta-analysis of observational studies as a tool for the purpose of 
exploration and exposure of the bias and heterogeneity that exists in a body of literature, as 
opposed to drawing direct conclusions from the aggregate effect measures [87]. Our study 
rationally completes this task and should serve as a caveat to the clinician that the exposure-
disease relationship between prior antibiotic use and NEC is complex and not easily modelled in 

























Table 1. Characteristics of studies included in qualitative analysis 
 
Studies  Exposure Study Design Participants Main results and risk estimates 
 Abdel- Ghany 
[162], 2012 




Retrospective cohort 207 VLBW neonates, survival >5 
days, had to have antibiotic 
exposure 
• Exposed: N= 173 
• Unexposed N= 34 
Outcome: NEC Bell’s stage II or greater 
Adjusted analyses: 
• Each additional day of antibiotic therapy 
increased odds of NEC; OR 1.31, CI95 (1.04, 
1.65) 
Adjusted for: SGA GA, gender, early enteral feeds, 
ROM > 24h, HTN, maternal hemorrhage, Lupus, 




Antibiotics used prior to onset of NEC; > 14 
days versus ≤ 14 days 
ampicillin/gentamicin or 




Prospective cohort 145 VLBW neonates, survival > 
14 days 
• Exposed: 83 
• Unexposed:62 
Outcome: NEC Bell’s stage II or greater 
Adjusted analysis: 
• Infants with >14days of antibiotic therapy: 
OR 3.09, CI95 (0.34, 28.34), p=0.32,  
Adjusted for: Birthweight, respiratory support, 






Empiric therapy for EOS >5 days versus ≤ 5 
days, Regimens not specified 
Dichotomous variable 
Retrospective cohort 295 neonates ≤ 32weeks and ≤ 
1500g 
 
• Exposed: N= 191 
• Unexposed N= 104 
Outcome: NEC not defined 
Unadjusted analyses: 
• Increased odds of NEC in the exposed group; 
OR 20.4,CI95(7.98, 52.4) 
Alexander [64], 
2011 
Empirical therapy, ampicillin/gentamicin, 
vancomycin, cefotaxime, clindamycin  
Both EOS and LOS included 
Continuous variable 
 
Case-control 372 neonates, mean GA 28 weeks 
• NEC-cases: 124 
• Controls: 248 
 
Outcome: NEC Bell’s stage II or greater 
Adjusted analyses - patients without sepsis prior to 
NEC 
• Increasing risk of NEC with increased 
duration of antibiotic exposure (~20% 
increased risk per day of exposure). OR 1.71 
CI95 (1.3-2.0) after 5-6 days of exposure 
Adjusted for: SGA, RDS, feeding composition, 











Administration of antibiotics initiated within 





glycopeptides, carbepenems, rifampicin, 
macrolides, nitroimidazole derivatives. 
Case-control 829 neonates, GA ≤30 weeks 
• NEC-cases: 56 
• Controls: 773 
Outcome: NEC Bell’s stage IIa or greater 
• Adjusted analyses - OR 0.227, CI95 0.079–
0.648 
Adjusted for: Sepsis, 5-minute Apgar, Antibiotic 
exposure prior, Enteral feeding, Mean daily enteral 
feeding volume increase during the first seven days 
postnatally, Achievement of full enteral feeding, 
total number of parenteral fed days 




Any therapy ≥5 days 





221 VLBW neonates, survival > 1 
week  
Outcome: NEC Bell’s stage II or greater 
• Adjusted analysis: OR 1.44  CI95 (0.57,4.72) 
Adjusted for CRIB-II score [proxy for gestational 
age, weight, and gender], sepsis, antenatal steroids, 




Choice and duration of empirical therapy  
• Period I (2010): ampicillin + 
cephalosporin 




Pre/post study 99 VLBW neonates 
• Period I: 57 
• Period II: 42 
 
Outcome: NEC Bell’s stage II or greater 
Mean (SD) duration of antibiotic exposure 
• Period I (2010): 41 (28) days; NEC 9/57 
(15.8%)  
• Period II (2011): 23 (20) days; NEC 1/42 
(2.4%) NEC 
• OR between epochs is 7.79, CI95 (0.93, 62.3) 
p = 0.041 




Empiric therapy, mainly ampicillin + 
gentamicin, for suspected EOS. 
Analyzed as both a continuous and 
categorical variable 
 
Retrospective cohort  4039 ELBW neonates, survival 
>5 days, received antibiotics in 
the initial 3 days of life, sterile 
blood cultures 
 
Outcome: NEC Bell’s stage II or greater 
Adjusted analyses: 
• Prolonged antibiotic therapy (≥ 5 days) not 
associated with increased odds of NEC alone 
OR = 1.21 CI95 (0.98, 1.51), p = 0.08 
o OR per day = 1.07 CI95 (1.04, 1.1) 
• Prolonged antibiotic therapy (≥ 4 d) 
associated with increased risk of NEC. OR= 
1.34 CI95 (1.04, 1.73) 
o OR per day = 1.09 CI95 (1.03, 
1.13) 
• Prolonged antibiotic therapy (≥ 5 days) 
associated with increased odds of NEC 1.50 
CI95(1.11–2.02), p <.01 in infants continually 
intubated through Day of life 7 
Adjusted for study center, gestational age, small-
for-gestational age status, gender, black race, 5-
minute Apgar score of <5, rupture of membranes 
for >24 hours, outborn, prenatal steroid treatment, 








hypertension, maternal hemorrhage, and multiple 
birth.   
Fajardo [164], 
2018 
Inital antibiotic therapy > 5 days duration 
Categorical variable 
Regimens not defined 
Retrospective cohort 
study 
620 neonates < 1250g 
 N = 238 with initial antibiotic 
duration >5 days 
N = 382 with initial antibiotic 
duration ≤5 days 
Necrotizing enterocolitis Bells stage II or greater 
• 1.58 CI95(0.54–4.61) 
Adjusted for gestational age, SNAP II, small-for-
gestational age status, gender, maternal 
hypertension, prenatal steroid treatment, clinical 
chorioamnionitis, intrapartum antibiotic treatment, 
and multiple births 
Greenwood 
[172], 2014 
Empiric therapy, mainly ampicillin/ 
gentamicin 
 
Prospective Cohort 74 preterm neonates ≤ 32 weeks 
N= 13 had no antibiotics 
N= 48 had a brief course of 
antibiotics 
N= 13 had intensive antibiotics 
Restricted, adjusted analysis:  
• No association difference in antibiotics 
use/outcome in restricted cohort of < 29w GA 
(p=0.208) 
Adjusted for birth weight, maternal hypertension, 
delivery mode, and extraction protocol 
Harms[157], 
1995 
Patients receiving a percutaneous central 
venous catheter (PCVC) received either: 
• amoxicillin 100 mg/kg/d prophylaxis 
until PCVC removed  
• No prophylaxis (control group) 
Dichotomous variable 
RCT 148 neonates receiving central 
venous catheters, all with BW < 
1500 
• Exposed: 75 
• Unexposed: 73 
 
NEC not defined 
• No significant difference between groups; OR 
= 0.32, CI95 (0.03, 3.1) 




Antibiotics used at day 7 of life, regimens not 
defined 
Dichotomous variable 
Prospective cohort 68 ELBW neonates, GA up to 27 
0\7  
• antibiotics at 7 days = 10/12 
infants with NEC  
• Antibiotics at 7 days  = 
37/56 infant without NEC 
 
“Stage II NEC” 
• No significant difference between groups; OR 
= 2.6, CI95 (0.4, 16.2) 




amoxicillin/clavulanate + gentamicin for 
EOS 
cephalothin/ gentamicin if suspected LOS 
Dichotomous variable 
Case-control 208 neonates, all GAs (median 
GA 29 weeks) 
• NEC-cases: 104 
• Controls: 104 
Outcome: NEC Bell’s stage II or greater 
Stepwise regression model, matched analysis: 
• Early (< 48 h) use of amoxicillin/clavulanate 
+ gentamicin reduced the risk of NEC; OR 
0.3, CI95 (0.2–0.6) 
Variables in model: Multiple pregnancy, RDS, 
neonatal corticosteroids, Inotropic support, 
umbilical catheterization, arterial catheterization, 
CVC, minimal enteral feeds, colonization with 












Antibiotics used prior to onset of NEC. 
Antibiotic regimens not specified. 
Dichotomous variable 
 
Case-control 701 Neonates 23 to 28 weeks  
• 234 Cases  
• 467 Controls  
Outcome: NEC Bell’s stage II or greater 
• No difference in antibiotic use in infants who 
developed NEC: OR 0.82, CI95 (0.39–1.72) 
Adjusted for: 
Inotrope use, presence of a PDA, SNAP-II scores, 
days NPO 
Matched on GA, BW, sex 
Kuppala [66], 
2011 
Prolonged initial antibiotic use; 0 days, 1-4 
days, ≥5 days 
Primarily ampicillin/ gentamicin (also 
clindamycin, nafcillin, cefotaxime) 
Categorical variable 
 
Retrospective cohort 365 neonates ≤ 32 weeks and ≤ 
1.5 kg, survival without sepsis or 
NEC for 7 days 
• A (No antibiotics): 60 (NEC 
= 0) 
• B (Antibiotics 1-4 days): 
175 (NEC = 8) 
C (Antibiotics ≥ 5 days): 130 
(NEC = 9) 
Outcome: NEC Bell’s stage II or greater 
Adjusted analyses: 
• Prolonged antibiotic therapy (≥ 5 days) not 
associated with risk of NEC; OR 1.28 
CI95(0.42-3.93) 
Adjusted for birth weight, gestational age, race, 
prolonged premature rupture of membranes, 
number of days on high frequency ventilation in 
first week of life, amount of breast milk received in 
first 14 days of life. 
Li  [171], 2015 Percent of neonates receiving ampicillin, 
cefoxitin, cefuroxime, or piperacillin plus 




1485 neonates between 34 and 42 
weeks, > 2kg, < 12 hours old;  
• Historical cohort: N= 
769 
• Intervention cohort: 
N= 716 
Outcome: NEC is not defined 
Historical cohort: N= 769, 421 (55%) given 
antibiotics, NEC = 2 (0.26%), Intervention cohort: 
N= 716, 252 (35%) given antibiotics NEC = 1 
(0.14%) 
• No difference in NEC between eras: OR = 
0.54, CI95 (0.05, 5.7) 
Multiple ANOVA for site and GA 
Martinez [165], 
2017 
Antibiotic therapy in the first 72 hours of life, 
regimens not specified 
Dichotomous variable 
 
Retrospective cohort 901 neonates < 1500g, survival 
for > 14days, TPN for > 3 initial 
days of life, adequate PNC, ≥ 
1dose of steroids, at low risk for 
sepsis 
• Exposed: 67 (8 NEC) 
• Unexposed 834 (28 NEC) 
Outcome: NEC mirrors NHSN criteria. 
• Increased odds of NEC in exposed infants, 
OR= 3.9,  CI95 (1.6, 9.7) 
Unadjusted analysis only 
Mufti [153], 
1992 
Antibiotics used prior to onset of NEC.  
Antibiotic regimens not specified. 
Dichotomous variable 
 
Case-control 39 neonates, ≤ 2 kg 
• NEC-cases: 9 
• Controls: 30 
Outcome: NEC Bell’s stage II or greater 
• NEC-cases:  9/9 (100%) 
• Controls: 25/30 (83%) 
No significant difference in antibiotic exposure 
between groups. Prior antibiotic therapy: RR 1.2, 
CI95 (0.84, 1.72) 








Ng [158], 2012 Oral erythromycin (5mg/kg/day) as treatment 
for feeding intolerance, versus placebo, 
q6hourly for 14 days 
Dichotomous variable 
RCT 45 VLBW neonates > 14 days old 
• Exposed 19 
• Unexposed 26 
Outcome: NEC Bell’s stage II or greater 
• Significant difference in NEC between groups 
by Fisher’s exact: p=0.016 
Unadjusted analysis only 
Nuntnarumit 
[159], 2006 
Oral erythromycin 10 mg/kg every 6 hours 
for 2 days, followed by 4 mg/kg every 6 
hours for another 5 days 
Dichotomous variable 
RCT 46 neonates < 35 and < 1800g and 
diagnosed with feeding 
intolerance 
•       23 exposed 
•       23 control 
Outcome: NEC Bell’s stage II or greater 
• No significant difference in NEC between 
groups OR = 0.3, CI95 (0.01,16.9) 
Unadjusted analysis only 
Raba [154], 
2019 
Empiric therapy for EOS;  
Prolonged exposure to initial antibiotics for > 
5 days  
Benzyl penicillin, amoxicillin, vancomycin, 
cefotaxime, meropenem, gentamicin 
Case-Control 54 VLBW neonates 
• 22 cases 
• 32 controls 
Outcome: NEC Bell’s stage II or greater 
Matched for gender, gestational age, sex, maternal 
chorioamnionitis, SGA, 1 and 5minute APGARS, 
and mode of delivery 




Antibiotic use prior to surgical intervention 
ampicillin, gentamicin, tobramycin, 
cefotaxime, ceftriaxone, clindamycin, 
cefepime, vancomycin, meropenem, 
metronidazole, piperacillin-tazobactam 
Continuous variable 
Not stated 26 neonates who underwent 
bowel surgery: 
• 12 with NEC 
• 14 without NEC 
Convenience sample of infant who underwent 
bowel surgery 
Unadjusted analysis 
P= 0.29 by t-test, mean = 11.83 
  95% confidence interval of this difference: From -
34.35 to 10.69, standard error of difference = 
10.858 
Shah [65],  
2013 
Empirical therapy for suspected EOS and 
LOS 
penicillin/gent for early onset sepsis 
vancomycin/gentamicin/meropenem, +/- 




Retrospective cohort 216 neonates < 28 weeks, survival 
>3 d 
• Antibiotics < 4 days: 96 
• Antibiotics ≥ 4 days: 120 
Groups not comparable:  
• Lower GA and more IUGR 
in “Antibiotics ≥ 4 days 
Outcome: NEC Bell’s stage II or greater 
Adjusted analyses: 
• Prolonged antibiotic therapy (≥4 d) not 
associated with increased odds of NEC and/or 





IV erythromycin infusion 15 mg/kg three 
times daily for the first 7 days 
RCT 76 neonates< 31w, on MV on  
DOL 1 
• 35 erythromycin 
• 41 placebo 
Outcome: NEC defined as pneumatosis on x-ray or 
surgical findings 
• No significant difference in NEC between 
groups, OR 0.56, CI95 (0.14, 2.24)  
Unadjusted analysis only 
Stoll [155], 
1980 
Antibiotics used prior to onset of NEC. 







• NEC-cases: 35 
• Controls: 98 
Outcome: NEC defined as clinical symptoms plus 








• No significant difference in antibiotic 
exposure between groups, yes/no: OR = 2.65, 
CI95(0.83, 8.845) 
BW and admission date matched  
Tagare [161], 
2010 
amoxicillin/clavulanate + amikacin for the 
first 5 postnatal days vs no antibiotics  
Dichotomous variable 
RCT 140 neonates < 37 weeks at low 
risk for infection 
• Exposed: 69 
• Unexposed: 71 
Outcome: NEC Bell’s stage II or greater 
• No significant difference in NEC between 
groups OR = 3.4, CI95 (0.94, 12.3) 
Unadjusted analysis only 
Ting [145], 
2019 
0, 1 to 3, and 4 to 7 days of antibiotics for 
EOS 
Dichotomous variable 
Regimens not described 
Retrospective cohort 
 
16560 VLBW infants (14207 
used) 
• 0 days antibiotics: 83 
cases/2950 infants 
• 1-3 days antibiotics: 177 
cases/5401 infants 
• 4-7 days antibiotics: 273 
cases/5856 infants 
 
3797 Low risk VLBW infants  
• 0 days antibiotics: 43 
cases/1512 infants 
• 1-3 days antibiotics: 36 
cases/1117 infants 




Outcome: NEC Bell’s stage II or greater 
Adjusted model: 
• 1-3 days versus 0: OR 0.74 CI95(0.55–0.99) 
• 4-7 days versus 0: OR 0.75 CI95 (0.56–1.02) 
• 4-7 days versus 1-3 days: OR  1.02 CI95(0.83–
1.25) 
 
Subgroup analyses of VLBW infants at low risk of 
EOS (born via cesarean delivery, without labor and 
without chorioamnionitis) and ELBW infant 
yielded similar findings;  
VLBW cohort: 
• 1-3 days versus 0: OR 0.79 CI95(0.49–1.27) 
• 4-7 days versus 0: OR 0.69 CI95 (0.42–1.12) 
• 4-7 days versus 1-3 days: OR  0.87  
CI95(0.55–1.39) 
 
Adjusted for GA, SNAP-II score >20, CRP, PROM 
≥24 hours, multiple births, surfactant use, 
mechanical ventilation for all first 3 days, inotropes 
in any of first 3 d, iNO in any of first 3 days, and 
pneumothorax treated with chest tube  




Median days of antibiotic exposure and 
percentage of infants with antibiotic use > 
48h 
primarily  ampicillin/gentamicin 
Retrospective cohort 
Pre/post 
674 VLBW neonates  
• 313 pre-ASO group 
• 361 post ASO group 
Outcome: NEC defined as pneumatosis on x-ray or 
surgical findings 
Reduced median antibiotic exposure (pre-ASO: 6.5 
DOT vs. Post-ASO: 4 DOT; p < 0.001), and a 
lower percentage of infants with antibiotic use > 48 
hours (63.4 vs. 41.3%; p < 0.001) 





Days of antibiotics prior to NEC 




Nested case control 53 Neonates ≤ 32w GA  
• 18 cases 
• 35 controls 
NEC not defined 
• Duration of antibiotic exposure prior to NEC 
did not differ between cases and controls 









• No differences in the individual antibiotics 
prescribed before diagnosis in NEC cases 
compared with controls  
Unadjusted analysis only 
Wang [59], 
2009 
Days of antibiotics prior to NEC 
Antibiotics used prior to onset of NEC. 
Antibiotic regimens not specified. 
Case-control 20 infants 25–32weeks GA 
• NEC-cases: 10 
• Controls: 10 
NEC not defined 
• Infants with NEC had more days of 
antibiotics days compared to control infants, 
p=0.005 
• Cases = 13.7±10.2 
• Control 3.7±3.0  
Unadjusted analysis only 



















Oral kanamycin, 15mg/kg divided TID 
immediately prior to the initiation of enteral 
feeds, for 24 days 
RCT 99 neonates < 36w or < 2250g 
• 49 intervention 
• 50 control 
Outcome: NEC defined as clinical symptoms plus 
pneumatosis, portal venous gas or free air 
• No significant difference in NEC between 
groups OR 0.3, CI95 (0.07, 1.37) 
Also stratified by use of prior IV antibiotics therapy 
Unadjusted analysis only  
Egan [51] 
1976 
Oral kanamycin, 15mg/kg divided TID upon 
initiation of enteral feeds, for 21 days 
RCT 75 neonates <1500g 
• 35 intervention 
• 40 control 
Outcome: NEC defined as abdominal distention or 
gastric residuals plus pneumatosis, portal venous gas 
or free air 
• 0 events in the intervention  group, 5 in the 
control group, OR 0.1, CI95 (0.01, 1.07) 
Unadjusted analysis only 
Grylack [52] 
1978 
Oral gentamicin 2.5mg/kg q6h for 7 days RCT 42 neonates < 1500g 
• 20 intervention 
• 22 control 
Outcome: NEC not defined 
• 0 events in the intervention  group, 4 in the 
control group, OR 0.1, CI95 (0.01, 1.57) 
Unadjusted analysis only 
Ng [54] 1988 Oral vancomycin 15mg/kg PO q8h for 6 
doses before feeds 
None 204 VLBW neonates who 
survived to start feeds 
• 84 exposed 
• 92  unexposed 
Outcome: NEC defined as abdominal distension, 
blood in the stools, and intramural gas on abdominal 
radiography. 
• Significant difference in NEC between groups, 
OR 0.052, CI95 (0.01, 0.3) (p <0.001) 
Unadjusted analysis only 
Rowley [55] 
1978 
gentamycin enteral 2.5mg/kg 6 hourly for 
one week 
RCT 100 “neonates” < 2kg 
•        50 exposed 
•        50 unexposed 
Outcome: NEC defined pneumatosis on radiograph 
• No significant difference in NEC between 
groups: OR= 0.2.14, CI95 (0.25, 18.3) 
Unadjusted analysis only 
Siu [53] 
1998 
Oral vancomycin 15mg/kg PO q8h for 7 days  RCT 140 infants with birthweight 
<1500g, 48 hours old 
• 71 exposed 
• 69 unexposed 
• Significant difference in NEC (Stage 2,3) 
between groups, OR = 0.38 








Gestational age (GA); Small for gestational age (SGA); rupture of membranes (ROM); hypertension (HTN); very low birthweight (VLBW); preterm premature 
rupture of membranes (PPROM); early onset sepsis (EOS0; late onset sepsis (LOS); respiratory distress syndrome (RDS); nil-per-os (NPO); total parenteral 
nutrition (TPN); extremely low birthweight infant (ELBW); central venous catheter  (CVC); percutaneous central venous catheter (PCVC); coagulase negative 









Study Reason for exclusion 
Greenwood [172] 2014 Aggregate outcome of NEC, death, LOS 
Romano-Keeler [173], 2018 Convenience sample of infants undergoing bowel surgery, prior antibiotics inclusive of those treating NEC 
















































































































         
Abdel- Ghany [162], 2012 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Afjeh [167], 2016 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Al-Mouqdad [163], 2018 + + + NA - + + Risk of Bias: Serious  
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Alexander [64], 2011 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Berkhout [151], 2018 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Decrease the 
effect estimate 
Tool used: ROBIN-I 
*Cantey [169], 2016 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias Increase the 
effect estimate 
Tool used: ROBIN-I 
Chang [170], 2013 + + + NA - + - Risk of Bias: Severe 
Direction of Bias 








Cotton [63], 2009 + + - NA - - + Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Fajardo [164], 2018 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias Increase the 
effect estimate 
Tool used: ROBIN-I 
Greenwood [172], 2014 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN- 
Harms [157], 1995 + + + NA - + + Risk of bias: High risk of bias 
Tool used: RoB2.0 
Jenke [168] 2013 + + + NA - + - Risk of Bias: Serious 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Krediet [69], 2003 + + + NA - + + Risk of Bias: Severe 
Direction of Bias: Decrease the 
effect estimate 
Tool used: ROBIN-I 
Kritsman [152]2015 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias Unclear 
Tool used: ROBIN-I 
Kuppala [66], 2011 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Li  [171] 2015 + + + NA - + + Risk of Bias: Severe 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Martinez [165] 2017 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Mufti, [153]1992 + + + NA - + + Risk of Bias: Severe 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Ng [158], 2012 + + + NA - + - Risk of bias: High risk of bias 
Tool used: RoB2.0 
Nuntnarumit [159], 2006 + + + NA - + + Risk of bias: High risk of bias 









Raba [154], 2019 + + + NA + + - Risk of Bias: Severe 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Romano-Keeler [173], 2018 + + + NA - + + Risk of Bias: Moderate 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Shah [65], 2013 + + + NA - + - Risk of Bias: Moderate 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Stenson [160] 1998 + + + NA - + - Risk of bias: High risk of bias 
Tool used: RoB2.0 
Stoll[155], 1980 + + + NA - + - Risk of Bias: High 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Tagare [161], 2010 + + + + - + + Risk of bias: High risk of bias 
Tool used: RoB2.0 
Ting [145], 2019 + + + NA + + - Risk of Bias: Moderate risk of 
bias 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Tolia [166] 2017 + + + NA - + - Risk of Bias: High risk of bias 
Direction of Bias: Increase the 
effect estimate 
Tool used: ROBIN-I 
Torraza [156] 2013 + + + NA - + + Risk of Bias: High risk of bias 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Wang [59], 2009 + + + NA - + + Risk of Bias: high 
Direction of Bias: Unclear 
Tool used: ROBIN-I 
Boyle [50] 1978 + + _ + - + + Risk of bias: High risk of bias 
Tool used: RoB2.0 
Egan [51] 1976 + + _ + - + - Risk of bias: High risk of bias 
Tool used: RoB2.0 
Grylack [52] 1978 + + _ - - + - Risk of bias: High risk of bias 









Ng [54] 1988 + + _ + - + - Risk of bias: High risk of bias 
Tool used: RoB2.0 
Rowley [55] 1978 + + _ - - + + Risk of bias: High risk of bias 
Tool used: RoB2.0 
Siu [53] 1998 + + _ - - + - Risk of bias: High risk of bias 











Figure 2: The overall analysis failed to provide evidence of an association between prior antimicrobial use 
and NEC when all 33 studies were included, with a summary OR of 1.13, CI95 (0.88, 1.45) and significant 


















Figure 3. Forest plot with summary measures from studies reporting prophylactic 
enteral antibiotic use prior to NEC 
 
Figure 3. The administration of prophylactic enteral antibiotics showed an overall significant reduction in 
NEC: OR 0.2 CI95(0.08, 0.54) and acceptable heterogeneity I2 = 35% 
 
Figure 4. Forest plot with summary measures from studies reporting antibiotic use prior to 




Figure 4. The analysis limited to studies describing prior antibiotic use excluding those for prophylaxis 
against NEC showed a trend towards a positive association between prior antibiotic use and NEC, but with 











Figure 6: Prior parenteral antibiotics 
 
 
Figures 5 and 6: Analysis of the use of prior antibiotics and the odds of NEC, stratified by mode of 
administration. The use of enteral antibiotics prior to NEC showed a consistent decrease in the odds of NEC 
with a summary OR of 0.37, CI95 (0.17, 0.8), I2 = 70% (Figure 5), while the prior use of parental antibiotics 
showed a positive association with NEC, but again with significant heterogeneity; OR 1.48, CI95 (1.18, 1.86), 












Figure 7. Prior Antibiotics, RCTs and cohort studies only                                        
 
 
Figure 8. Prior antibiotics, RCTs only 
 
 Figures 7 and 8: Analysis by study type, with sequential elimination of study type by perceived risk of bias 
showed no effect of prior antibiotics on NEC with a summary OR of 1.19, CI95 (0.79, 1.79), I2 = 75% (Figure 






Figure 9. Studies reporting antibiotic use prior to NEC 
9a. Plot of I2 versus credibility ceiling                       9b. Sensitivity analysis of credibility ceilings 
 
Figure 9: A sensitivity analysis performed over a range of credibility ceilings (0-40) for overall use of 
antibiotics prior to NEC (OR 1.13, CI95 [0.88, 1.45] I2 = 77%) shows heterogeneity first reaching an estimate 




















Figure 10. Studies reporting antibiotic use prior to NEC excluding those for prophylaxis 
10a. Plot of I2 versus credibility ceiling 
 
 
10b. Sensitivity analysis of credibility ceiling 
 
Figure 10: A sensitivity analysis performed over a range of credibility ceilings (0-40) for the analysis that was 
limited to studies describing prior antibiotic use excluding those for prophylaxis against NEC (OR 1.31, CI95 
[1.02, 1.67], I2 = 77%) shows heterogeneity first reaching an estimate of 0% at a ceiling of 12% (Fig. 10a); 









Figure 11. Studies reporting prior parenteral antibiotics 






11b. Sensitivity analysis of credibility ceiling 
 
Figure 11: A sensitivity analysis performed over a range of credibility ceilings (0-40) for the analysis 
restricted to prior use of parental antibiotics (OR 1.48, CI95 [1.18, 1.86], I2 72) shows heterogeneity first 
reaching an estimate of 0% at a ceiling of 10% (Fig. 11a); nominal statistical significance is maintained 
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Appendix C: Credibility Ceiling, c% Background  
c% Rationale [83-86, 174, 175] 
For a meta- analysis of n studies, each with an effect size yi with variance vi under a random-
effects meta-analysis model, the likelihood of each study will be a function of the true underlying 
random effect θi, the common mean effect μ, and the heterogeneity variance τ2:    
The likelihood function of this meta-analysis model will then be: 
 
The random effects model inflates the variance of the pooled effect to incorporate heterogeneity, 
such that  but the CIs may still be insufficiently narrow to include all the 
factors of uncertainty and bias. 
In a single study, there is at least “c” probability that the underlying effect is not in the direction 
of the effect suggested by the observed point estimate yi. This credibility ceiling can’t be reduced 
further, regardless of how large and meticulous the study is. A single study of this type can never 
give more than (1−c)/c certainty that the effect is in the direction suggested by the point estimate 
versus not in this direction, if an effect does exist. Several studies replicating an effect in that 
direction are required to exceed this level of certainty. Within-study variances are inflated to 
leave a c% chance to observe findings in the opposite direction suggested by the point estimate. 
This is relevant because clinicians will often cherry-pick a study that is recent, or familiar.  
c% Mechanics 
To determine the probability that an observed effect with sampling variance vi would be on the 
opposite direction of the true effect a random variable μi ∼N(yi,vi) is created. The probability that 






If this probability is less than the chosen “c” then the variance is recalculated  
as: 
where z= the inverse of the cumulative normal distribution. 
The new study-specific likelihood functions with the inflated variances are then synthesized 
according to inverse variance meta-analysis methods, and the variance of the summary effect 
estimate is further inflated where: 
This is then repeated as a “sensitivity analysis” for a range of c%. These ranges are determined 
by prior knowledge, but generally run at 1-40, in increments of 1. 
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Appendix E: Neonatal Sepsis Guidelines for Tufts Floating Hospital for 
Children and BronxCare Hospital System 
 
E1. Evaluation for Neonatal Early-Onset Sepsis in the Tufts Floating Hospital for Children 
MIU  
The Neonatal Early-Onset Sepsis Calculator is a well-researched tool that may be used to guide 
management of well appearing newborns at risk for sepsis.  The calculator can be accessed at 
https://neonatalsepsiscalculator.kaiserpermanente.org/ or newbornsepsiscalculator.org on your 
smart phone.    
Target Population:  newborns >35 weeks gestation eligible for admission to MIU with any risk 
factors for sepsis.  Risk factors for sepsis include the following:  
➢ Maternal temperature >100 during labor  
➢ GBS positive mother inadequately treated (Adequate prophylaxis is defined as 
Ampicillin, Penicillin or Cefazolin administered at least 4 hours prior to delivery)  
➢ Mother with prolonged rupture of membranes (>18 hours) 
➢ Mother diagnosed with “chorioamnionitis”  
Exclusion criteria: Ill-appearing babies or babies admitted to NICU should be managed based 
on clinical evaluation.  Infants whose mother develop fever or signs of infection within 12h post-
partum are still at risk for early onset sepsis and require evaluation, but are not eligible to be 
screened with the Calculator.  
Using the Calculator:  This calculator uses 5 perinatal predictors in conjunction with the 
infant’s clinical appearance to produce the individual risk of Early Onset Sepsis (EOS) for the 





Illness”, “Equivocal”, or “Well-Appearing”.  Evaluation should be done immediately after birth 
for babies with risk factors for sepsis.  It may be used by nursing or physicians.           
 
Predictor Scenario 
Incidence of Early-Onset Sepsis Use “0.5/100 live births (CDC national 
incidence)” 
Gestational age Input weeks and days 
Highest maternal antepartum temperature Select Fahrenheit or Celsius 
ROM (Hours)  
Maternal GBS status Negative, Positive, Unknown 
Type of intrapartum antibiotics *Broad spectrum, GBS specific, or none; 
and time given prior to birth 
*GBS specific =single agent Penicillin, Ampicillin, Clindamycin, Cefazolin or Vancomycin 






Clinical appearance is defined as follows:  
“Well-appearing” babies have normal vital signs 
“Equivocal” babies have one of the following symptoms for >4 hours or 2 symptoms for >2 
hours 
➢ Tachycardia with HR > 160 
➢ Tachypnea with RR > 60 
➢ Temperature instability >100.4 or <97.5 
➢ Mild respiratory symptoms (flaring, grunting) not requiring oxygen   
“Clinical Illness” includes respiratory failure requiring CPAP/ventilator, hypotension requiring 
pressors, seizures, hypoxic encephalopathy (babies who would be in NICU)  
Clinical Recommendation will be based on calculated risk and may include observation, labs 
and observation, or labs and antibiotics.   
• The baby’s clinical appearance guides management and must be monitored:  
o Babies should have vital signs as per calculator recommendations and nursing 
staff should be told to page MD for tachypnea (RR>60) tachycardia (HR>160) 
respiratory distress or temperature instability (temperature >100.3 or <97.5).    
o Babies requiring Q4 hour vital signs will have a crib card identifying them as 
being on a “sepsis watch.” 
o Babies who develop tachycardia, tachypnea, respiratory distress or temperature 
instability should be immediately re-evaluated and the case should be discussed 






• If a blood culture is recommended, this may be delayed no more than 1-2 hours after 
birth to allow for maternal-infant bonding in the immediate post-partum period.  The 
blood culture may be done in the labor suite or MIU by an RN or MD. 
o Other labs (ie, CBC, CRP) are not recommended, but may be obtained at the 
discretion of the MIU or NICU attending. However, it should be noted that: 
▪ Abnormal labs have a low positive predictive value for sepsis in a well 
appearing baby 
▪ Serial values, starting at >4h of life may be more informative than isolated 
values drawn at birth 
 
• Babies whose mother develop fever or signs of infection within 12h post-partum should 
have vital signs monitoredQ4h, and should be discussed on a case-by–case basis with the 
MIU attending. 
The recommendations of any screening tool or value should not supersede good clinical 
judgment. 
Documentation: Admission note for baby should be charted shortly after birth and include risk 
factors for sepsis, vital signs, physical examination, use of the calculator and risk of EOS.  Plan 
of care should include close monitoring for the first 24 hours of life.  Should baby’s condition 
and plan of care change, an event note should be documented.   
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E2. BRONXCARE CLINICAL PRACTICE GUIDELINE: 




To provide guidance for the diagnosis and antimicrobial treatment of infants at risk for or with 
confirmed EOS born at BronxCare Health System 
 
GENERAL STATEMENT OF PURPOSE 
1. Provide updated clinical guidelines for the pediatric/neonatal team to ensure that infants at risk 
for or with confirmed EOS are evaluated promptly and treated appropriately when necessary 
2. Provide guidelines for judicious choice and use of antimicrobials given the long term side 
effects including alteration of the intestinal microbiome, increased hospital length of stay and 
emergence of antibiotic resistant organisms (ARO) 
3. Encourage diagnostic stewardship to avoid the use of unnecessary and painful procedures that 
have low sensitivity and specificity for neonatal sepsis 
 
DEFINITIONS 
Early-Onset Sepsis (EOS): culture proven blood stream infection and/or meningitis that occurs in 
infants within the first 3 days of life, or within the first 7 days of life for infants continuously 
hospitalized in the NICU. They are acquired most commonly intrapartum and reflect maternal 






Intrapartum antibiotic prophylaxis for GBS:  
• Intrapartum prophylaxis for GBS  is indicated if there is a positive screening culture done 
at 35-37 weeks gestation during current pregnancy, GBS bacteriuria during current 
pregnancy, previous child with invasive GBS disease; GBS unknown status or GBS 
expired ((culture done > 35d prior to onset of labor) and a gestational age  < 37 weeks, 
ROM ≥ 18 hours  
• Antibiotic prophylaxis is not indicated in women with a positive prenatal GBS culture 
result who undergo a cesarean birth before the onset of labor and with intact membranes  
• Adequate antibiotic Prophylaxis for GBS are Ampicillin, Penicillin, or Cefazolin. 
Clindamycin and vancomycin ARE NOT considered adequate intrapartum prophylaxis. 
• GBS specific antibiotics are Ampicillin, Penicillin, or Cefazolin 
• The optimal antibiotic treatment window is ≥ 4 hours before birth.  
o Although a shorter duration of intrapartum antibiotic administration is less 
effective than ≥ 4h of prophylaxis, 2 hours of antibiotic exposure has been shown 
to reduce GBS vaginal colony counts and decrease the frequency of a clinical 
neonatal sepsis diagnosis 
▪ All antibiotics used for GBS prophylaxis rapidly reduce maternal GBS 
colony counts and achieve bactericidal levels in amniotic fluid and cord 
blood within 2 hours of maternal administration 
• Broad spectrum antibiotics are for the purposes of this guideline are 2 or more different 
antibiotics (ie, Ampicillin + Gentamicin), or combination antibiotics such as 








RISK FACTORS FOR EARLY ONSET SEPSIS 
Maternal • Intrapartum fever1 (within 1 hour of delivery of 
the placenta) 
• Duration of ROM 
• Maternal colonization with GBS 
• Diagnosis of chorioamnionitis/intra-amniotic 
infection1 
• Type and timing of intrapartum 
antibiotic administration2 
• Premature labor and premature ROM 
  
Neonatal • Gestational age3 
• Need for resuscitation, perinatal depression 
• Clinical instability during hospitalization4 
  
Community Incidence of early onset sepsis 
 
1. Chorioamnionitis is a primarily a clinical diagnosis, consisting of maternal fever >38.0 and 
maternal signs and symptoms including elevated WBC, uterine tenderness, fetal and maternal 
tachycardia, etc. The American College of Obstetrician and Gynecologists (ACOG) have 
superseded this with the preferred term of intraamniotic infection. Intraamniotic infection is 
further divided into three different categories: 1) isolated maternal fever, 2) suspected 
intraamniotic infection, and 3) confirmed intraamniotic infection. In practice, these are 
obstetrical constructs that are often used interchangeably, clinicians often choose to treat 
isolated maternal fever as intraamniotic infection, and ACOG recommends treating suspected 
and confirmed intraamniotic infection the same. 
2. A paradigm shift is the belief that the administration of intrapartum antibiotics renders a 
blood culture taken from the infant to be unreliable; ie, that an actually infected infant will 





a. Intrapartum antibiotics are by definition given to prevent neonatal sepsis. As pointed 
out above, many commonly administered antibiotics have been shown to achieve 
amniotic fluid and cord blood levels that reduce amniotic and vaginal colony counts; 
as such, the administration of that these antibiotics provide protection to the infant, 
especially when administered >4 hours prior to delivery. 
b. Blood culture systems such as the BD BACTEC™ Peds Plus contain optimized 
enriched culture media with antimicrobial neutralization properties that can reliably 
detect bacteremia at a level of 1 to 10 colony-forming units per mL if a minimum 
blood volume of 1 mL is inoculated.  
3. The risk of sepsis increases at <37 week gestational age, with an additional uptick in risk at 
>40 weeks gestation. 
4. Non bilious emesis in an otherwise well appearing infant with a reassuring abdominal exam 














RISK ASSESMENT AND MANAGEMENT GUIDELINE IN INFANTS ≥36 WEEKS 
GESTATIONAL AGE USING THE EOS RISK AT BIRTH SCORE (EOS SCORE) 
Infants with signs of sepsis should be referred to NICU for evaluation. Further management will 
be determined by the infant’s clinical status, not by the EOS Score 
i. Well-appearing, asymptomatic infants who meet the following criteria (not displaying signs 
or symptoms of sepsis) will have EOS Score calculated to guide management (strong 
recommendation, moderate quality evidence – large cohort data [3-7,9]) 
a. ≥ 36 weeks AND 
b.  Whose mother were diagnosed with or treated during labor or within 1 hour after 
delivery for maternal fever, chorioamnionitis or intraamniotic infection  
i. Infants who are eligible to be admitted to the TCN for low APGARS, need for 
resuscitation at birth, GBS unknown and/or inadequately treated may be 
scored at the discretion of the TCN attending 
ii. Scheduled C-sections with intact membranes and no signs of labor should not be scored 
(strong recommendation, low quality evidence – unwise use of resources due to low risk 
of sepsis in this population) 
iii. Symptomatic or ill-appearing infants should not be scored (notify NICU immediately) 
(strong recommendation, moderate-quality evidence) 
iv. The EOS Score can be accessed and calculated at the following WEBSITE: 
https://neonatalsepsiscalculator.kaiserpermanente.org/  and input the following data from EMR 
into the data fields on the website 






b. Gestational age – at birth in weeks (36-43) and days (0-6) 
c. Highest maternal temperature during labor. If maternal fever is noted within 1 
hour after delivery, recalculate the score using the highest maternal temperature. 
d. Duration of ROM rounded up to the nearest hour. If ROM is unknown, estimate 
based on history or onset of labor 
e.  Maternal GBS status  
f. Type of intrapartum antibiotic prophylaxis - antibiotics given during labor. Note 
the timing of administration relative to delivery 
i. “Broad spectrum antibiotics” as defined above 
ii. “GBS-specific antibiotics” = ampicillin, penicillin or cefazolin 
iii. “No antibiotics” = choose if no antibiotics are given, if antibiotics were given 
< 2 h before delivery, OR if clindamycin or vancomycin were used for GBS 
prophylaxis  
g. Choose “Calculate” 
h. Use “EOS Risk @ Birth score” from TOP LINE of output (DO NOT use scores and 
clinical recommendations from the boxes at the bottom of the table) 






1. Level of care is determined by the EOS Score for well-appearing infants ≥ 36 weeks 
gestation (strong recommendation, low quality evidence – recommendations made to 
balance between desirable and undesirable outcomes, acceptability and feasibility; 
local challenges in inability to have enhanced monitoring in nursery) 
a.  EOS score < 1: Infant admitted to TCN. Infant stays with mother. No labs or 
antibiotics are needed. Vital signs are done as per usual newborn routine.  
b. EOS Score 1- >3: 
i. Admission to NICU 
ii. Blood culture is done at birth  
iii. If blood culture remains negative and infant remains well, infant may be 
transferred to newborn nursery at 24 hours of life. 
iv. Infant to remain in the hospital until 36-48h of life 
c. EOS Score ≥3: Admission to NICU: Blood culture is done at birth and empiric 
antibiotics are initiated 
 
LABORATORY SCREENING 
1. Blood culture should have a minimum volume of 1.5 ml of blood; 2ml is preferred 
(strong recommendation, moderate quality evidence) 
2. Consider lumbar puncture prior to initiation of antibiotics if meningitis is suspected and infant 






3. CBCs performed at the time of birth have a low sensitivity for detecting infected infants. 
If a clinician wishes to perform a CBC, waiting until 6-12 hours after birth is 




1. Ampicillin 50mg/kg IV q12h (strong recommendation, moderate quality evidence) 
a. Ampicillin 100mg/kg IV q8h if concern for meningitis (strong recommendation, 
moderate quality evidence) 
2.  Gentamicin 4mg/kg IV q24h (strong recommendation, moderate quality evidence) 
a. Gentamicin levels should not be drawn in infants in whom antibiotics are not 
going to be continued beyond 72h unless there is high degree of concern for renal 
compromise, such as in infants with severe renal malformations or asphyxia with 
renal damage (strong recommendation, low quality evidence- 
recommendations made to balance between desirable and undesirable 
outcomes: pain of procedure, need to minimize blood sampling, use of testing 
resources) 
3. Cefotaxime 50mg/kg/dose q12h should be added to ampicillin and gentamicin if there is 
suspicion of meningitis (strong recommendation, low quality evidence- Good Practice 
Statement) 
a. Ceftazidime 30mg/kg IV q12h should be used in the event cefotaxime is not 






4. Therapy should be limited to 4 doses of ampicillin and 2 doses of gentamicin if culture 
remains negative (strong recommendation, moderate quality evidence) 
a. Duration of course may be shortened at the discretion of the neonatologist (weak 
recommendation, low quality evidence)  
5. Consult ID of the mother has a known multi-drug resistant gram negative, VRE or other 
significant infectious disease history that may influence infant’s empiric therapy 
6. Consult ID if there is concern for meningitis 
TARGETED TREATMENT 
All positive cultures in infants evaluated for early onset sepsis require a Pediatric 
Infectious Disease consultation.  
This document is intended as a general guideline. The healthcare professional must use the 
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E3. BRONXCARE CLINICAL PRACTICE GUIDELINE: 




To provide guidance for the diagnosis and antimicrobial treatment of infants at risk for or with 
confirmed EOS born at BronxCare Health System 
 
IINTRODUCTION AND GENERAL STATEMENT OF PURPOSE 
Antimicrobials are the most frequently prescribed medications in the neonatal intensive care unit 
(NICU), with some centers reporting >95% of extremely low birthweight (ELBW) infants 
having exposure to at least one antimicrobial during their hospitalization. The adverse 
consequences of antibiotic exposure in the neonate include colonization and infection with 
antibiotic resistant organisms (ARO), dysbiosis, the alteration of the gut microbiome and 
subsequent development of aberrant intestinal microbiotia.  In preterm infants, early and 
prolonged antibiotic administration may contribute to poorer outcomes such as NEC, late onset 
sepsis (LOS) and overall mortality. However, EOS remains a serious and often fatal illness 
among premature infants, with mortality of 30% at 25–28 weeks, and approximately 50% at 22–
24 weeks gestational age.  
 
Gestational age is the strongest predictor of EOS; many preterm births are associated with 
preterm labor, PROM, or non-reassuring fetal status, and chorioamnionitis, or intraamniotic 






The majority of premature infants will have some respiratory or systemic instability as an 
expected part of physiologic immaturity, so risk stratification tools used for term infants cannot 
be applied to preterm infants. A diagnosis of EOS is also difficult to establish using laboratory 
tests, as patterns of blood count indices and markers of inflammation overlap between EOS and 
conditions that affect the fetus such as placental insufficiency.   
 
It is understandable that the uncertainty in EOS risk assessment and the catastrophic 
consequences of untreated sepsis often weight the balance towards initiation of antibiotics in the 
preterm population. 
The circumstances of preterm birth may provide the best approach to guide EOS management in 
preterm infants. 
 
The goals of these guidelines are not to supersede clinical judgement, rather to: 
1. Provide updated clinical guidelines for the neonatal team to ensure that infants at risk for 
EOS are evaluated promptly and treated appropriately when necessary 
2. Determine infants who are at lower risk for EOS and may be spared administration of 
empiric antibiotics 
3.  Provide guidelines for judicious choice and use of antimicrobials and to mitigate the 
negative consequences including alteration of the intestinal microbiome, emergence of 
ARO, NEC, LOS and overall mortality 
4. Encourage diagnostic stewardship to avoid the use of unnecessary and painful procedures 









Early-Onset Sepsis (EOS): culture proven blood stream infection and/or meningitis that occurs in 
infants within the first 3 days of life, or within the first 7 days of life for infants continuously 
hospitalized in the NICU. They are acquired most commonly intrapartum and reflect maternal 
flora, such as Beta-hemolytic Streptococcus Group B (GBS) and Escherichia coli. Listeria 
monocytogenes, other Streptococci as well as anaerobic species and Ureaplasma are also 
implicated in EOS in preterm infants. 
 
RISK FACTORS FOR EARLY ONSET SEPSIS 
Maternal • Intrapartum fever1 (within 1 hour of delivery of 
the placenta) 
• Duration of ROM 
• Maternal colonization with GBS 
• Diagnosis of chorioamnionitis/intra-amniotic 
infection1 
• Type and timing of intrapartum 
antibiotic administration2 
• Premature labor and premature ROM1 
  
Neonatal • Gestational age3 
• Need for resuscitation, perinatal depression 
• Clinical instability during hospitalization 
  
Community Incidence of early onset sepsis 
 
5. Chorioamnionitis is a primarily a clinical diagnosis, consisting of maternal fever >38.0 and 
maternal signs and symptoms including elevated WBC, uterine tenderness, fetal and maternal 
tachycardia, etc. The American College of Obstetrician and Gynecologists (ACOG) have 
superseded this with the preferred term of intraamniotic infection (IAI). As mentioned 





fetal status, and chorioamnionitis, or intraamniotic infection (IAI) is often the inciting factor 
for these conditions.  
6. A paradigm shift is the belief that the administration of intrapartum antibiotics renders a 
blood culture taken from the infant to be unreliable; ie, that an actually infected infant will 
have a falsely negative blood cultures.  
a. Intrapartum antibiotics are by definition given to prevent neonatal sepsis. As pointed 
out above, many commonly administered antibiotics have been shown to achieve 
amniotic fluid and cord blood levels that reduce amniotic and vaginal colony counts; 
as such, the administration of that these antibiotics provide protection to the infant, 
especially when administered >4 hours prior to delivery. 
b. Blood culture systems such as the BD BACTEC™ Peds Plus contain optimized 
enriched culture media with antimicrobial neutralization properties that can reliably 
detect bacteremia at a level of 1 to 10 colony-forming units per mL if a minimum 
blood volume of 1 mL is inoculated.  
7. The risk of sepsis increases at <37 week gestational age. The CDC national incidence of 0.5 
cases per 1000 infants in born at ≥37 weeks’ gestation can be compared with 1 case per 1000 
infants born at 34 to 36 weeks’ gestation, 6 cases per 1000 infants born at <34 weeks’ 
gestation, 20 cases per 1000 infants born at <29 weeks’ gestation, and 32 cases per 1000 
infants born at 22 to 24 weeks’ gestation. 
RISK ASSESMENT AND MANAGEMENT GUIDELINE IN INFANTS <36 WEEKS 
GESTATIONAL AGE  
Delivery characteristics of extremely preterm infants present an opportunity to identify those 





v. Infants at highest risk for sepsis: born due to cervical incompetence, preterm labor, PROM, 
chorioamnionitis/IAI, and/or unexplained onset of nonreassuring fetal status should be 
evaluated for sepsis and started on empiric antibiotic therapy (strong recommendation, high 
quality evidence) 
a. Infants between 33-35 weeks who are clinically well may be evaluated for EOS but 
have empiric antibiotics deferred at the discretion of the neonatologist (weak 
recommendation, low quality evidence) 
vi.  Infants at lower risk for sepsis: should NOT be evaluated for sepsis and started on empiric 
antibiotic therapy (strong recommendation, low quality evidence - unwise use of 
resources due to low risk of sepsis in this population, balance between desirable and 
undesirable outcomes due to injudicious use of antibiotics).  
These infants 
a. Have indications for delivery that are noninfectious in nature, such as maternal 
hypertensive disease, placental insufficiency, fetal growth or anatomic concerns AND 
b. Are delivered by cesarean delivery AND 
c. There is no labor, attempts to induce labor, or ROM prior to delivery 
vii. Infants who have indications for delivery that are noninfectious in nature as described above 
but deliver vaginally or cesarean delivery after induction of labor and/or ROM before 
delivery are at risk for EOS through ascending colonization and infection of the uterine 
compartment with maternal commensal flora. In these infants: 
a. Evaluation for EOS is recommended (weak recommendation, low quality evidence) 







4. Blood culture should have a minimum volume of 1 ml of blood for infants <750g, 1.5ml 
for ≥750g. 2ml is preferred (strong recommendation, moderate quality evidence) 
5. Consider lumbar puncture prior to initiation of antibiotics if meningitis is suspected and 
infant able to tolerate procedure (strong recommendation, moderate quality evidence) 
6. CBCs performed at the time of birth have a low sensitivity for detecting infected infants. 
If a clinician wishes to perform a CBC for other reasons than to check baseline red blood 
cell indices and platelets, waiting until 6-12 hours after birth is recommended (strong 
recommendation, moderate quality evidence) 
 
EMPIRIC TREATMENT 
       7. Ampicillin 50mg/kg IV q12h (strong recommendation, moderate quality evidence) 
a. Ampicillin 100mg/kg IV q8h if there is concern for meningitis (strong 
recommendation, moderate quality evidence) 
 
8.  Gentamicin Dosing- Based on Post menstrual age (corrected gestational age) (strong 
recommendation, low quality evidence - Good Practice Statement; data from the I-ACT 
collaboration pending) 
PMA Dose (mg.kg) Interval (hours) 
≤29 weeks 5mg/kg 48h 
30-34 weeks 4.5mg/kg 36h 






9. Gentamicin levels should not be drawn in infants in whom antibiotics are not going to be 
continued beyond 72h unless there is high degree of concern for renal dysfunction 
(strong recommendation, low quality evidence- recommendations made to balance 
between desirable and undesirable outcomes: pain of procedure, need to minimize 
blood sampling, use of testing resources ) 
10. Cefotaxime 50mg/kg/dose q12h should be added to ampicillin and gentamicin if there is 
suspicion of meningitis (strong recommendation, low quality evidence- Good Practice 
Statement) 
b. Ceftazidime 30mg/kg IV q12h should be used in the event cefotaxime is not 
available (strong recommendation, low quality evidence – AAP practice 
recommendation) 
11. Therapy should be limited to 4 doses of ampicillin and 2 doses of gentamicin for q24h 
and q36h dosing, 1 dose of gentamicin for q48h dosing, if culture remains negative 
(strong recommendation, moderate quality evidence- large cohort and PK modelling 
data) 
12. Fluconazole prophylaxis, 6 mg/kg (IV or OG) twice weekly (for up to 6 weeks if started 
at birth) , in neonates with birth weights <1000 g may be considered, especially in infants 
being treated with >72h of continuous antibiotic therapy, on antibiotic therapy for culture 
proven sepsis or NEC or receiving  a course of systemic steroids for lung disease. (strong 
recommendation, strong quality evidence) 
13. Consult ID of the mother has a known multi-drug resistant gram negative, VRE or other 
significant infectious disease history that may influence infant’s empiric therapy 







All positive cultures in infants evaluated for early onset sepsis require a Pediatric 
Infectious Disease consultation 
This document is intended as a general guideline. The healthcare professional must use the 
appropriate judgment dependent on the particular clinical situation 
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E4. BRONXCARE CLINICAL PRACTICE GUIDELINE: 
Risk Assessment and Management of Late Onset Neonatal Sepsis (LOS) in Infants 
Hospitalized in the Neonatal Intensive Care Unit 
 
CLINICAL CONTEXT: 
To provide guidance for the diagnosis and antimicrobial treatment of infants at risk for or with 
confirmed LOS in the NICU at BronxCare Health System 
 
IINTRODUCTION AND GENERAL STATEMENT OF PURPOSE 
Antimicrobials are the most frequently prescribed medications in the neonatal intensive care unit 
(NICU), with some centers reporting >95% of extremely low birthweight (ELBW) infants 
having exposure to at least one antimicrobial during their hospitalization. The adverse 
consequences of antibiotic exposure in the neonate include colonization and infection with 
antibiotic resistant organisms (ARO), dysbiosis, candidiasis and NEC.  Prolonged and repeated 
uses of antibiotics, especially broad spectrum agents such as carbapenems and cephalosporins 
are especially indicated in these consequences. 
 
Birthweight is a strong predictor of LOS; among infants < 750 g birth weight, the cumulative 
incidence of LOS is >40%. Objective assessment of risk is often confounded by the overlap in 
signs of LOS versus expected preterm behavior such as respiratory instability, apnea and feeding 
intolerance  
Lack of data-based guidelines for empiric antibiotic choice often mean that initial choice is 
driven by local expert practice and custom and may have ahigh degree of inter-and intra-provider 
variability.  Even in the case of proven disease, duration and choice of therapy are not well 






The goals of these guidelines are not to supersede clinical judgement, rather to: 
1. Provide updated clinical guidelines for the neonatal team to ensure that infants at risk for 
LOS are evaluated promptly and treated appropriately when necessary 
2. Provide guidelines for judicious choice and use of antimicrobials and to mitigate the 
negative consequences including alteration of the intestinal microbiome, emergence of 
ARO, NEC and overall mortality 
3. Encourage diagnostic stewardship to avoid the use of unnecessary and painful procedures 




Late-Onset Sepsis (LOS): culture proven that occurs in infants the first 7 days of life for infants 
continuously hospitalized in the NICU. LOS is acquired by horizontal transmission of pathogens, 
and typically reflect the local “microbiome” of the NICU.  
 
Gram-positive organisms account for the majority (50-75%) of LOS. Of the Gram-positive 
organisms, coagulase-negative Staphylococci (CONS) are the most prevalent, followed by 
Staphylococcus aureus. Beta-hemolytic Streptococcus Group B (GBS) are a rarer cause of LOS, 
and Enterococcal species may cause urinary tract infections (UTI).  Escherichia coli, Klebsiella 
species, Enterobacter species and Pseudomonas species may cause bacteremia, UTI and 
meningitis, and may cause fulminant sepsis.  Candida species is a significant cause of LOS in 





indolent course, and it is often difficult to define and infection with CONS species from a single 
positive blood culture. The majority of mortality occurs due to gram negative (especially 
Pseudomonas species) infection and invasive candidiasis. 
Meningitis is more common in LOS than EOS; it is likely under-diagnosed, as CSF sampling is 
often deferred as part of the initial evaluation. Multi-center surveys have shown that as few as 
31% of infants with positive CSF cultures had simultaneous positive blood cultures. 
 
Central line: An intravascular catheter that terminates at or close to the heart, or in one of the 
great vessels that is used for infusion, withdrawal of blood, or hemodynamic monitoring. For the 
purposes of our NICU, this includes any umbilical line (arterial or venous), a PICC line or a 
surgically placed central line such as a Broviac. 
 
For the purposes of this guideline, the following infections will be defined: 
• Urinary Tract Infection (UTI): There is at present no formal definition of a neonatal 
UTI. Growth of ≤ 2 organisms from a catheterized or suprapubic urine sample at ≥ 50, 
000 colony-forming units (CFU) per milliliter, or ≥ 10, 000 CFU/mL in association with 
a positive dipstick test or urinalysis is considered for this guideline (weak 
recommendation, low quality evidence) 
• Blood stream infection: A recognized pathogen cultured from one or more blood 
culture. 
o If the patient has a central line in place for > 2 calendar days on the date of the 
positive blood culture (with day of device placement being Day 1) AND the 





Control Committee may define this as a Central Line Associated Blood Stream 
Infection (CLABSI) 
o Additional CLABSI criteria: 
▪ Organism cultured from blood is not related to an infection at another site 
(ie, urosepsis) 
▪ If the organism is a commensal, or potential contaminant bacterial such as 
CONS, the same organism is cultured from two or more blood cultures 
drawn on separate occasions 
• Necrotizing enterocolitis (NEC): a serious intestinal condition with at least one of the 
clinical and one of the imaging test findings from the lists below and a consistent clinical 
course: 
o Clinical signs: bilious aspirate (with a normally placed gavage tube), vomiting, 
abdominal distention, occult or gross blood in stools (with no rectal fissure) 
o Findings on imaging test: pneumatosis intestinalis, portal venous gas, 
Pneumoperitoneum 
• Ventilator associated pneumonia (VAP): There is at present no validated definition for 
neonatal ventilator associated pneumonia. However, most experts accept a diagnosis of 
VAP when the following are present in an infant who has been ventilated for ≥ 4 days 
(weak recommendation, low quality evidence) 
o New and persistent radiographic infiltrates 





o Clinical criteria such as temperature instability, change in the characteristics of 
respiratory secretions, worsening distress on the ventilator, hemodynamic 
instability 
o Microbiologic data should be taken with caution, as it is difficult to distinguish 
upper respiratory commensal organism from a bacterial “cause” of disease, and 
WBC indices may have both inter-and intra-lab variability  
• Skin infection: Infections of the skin or soft tissue, including omphalitis. This does not 
include osteomyelitis or post-operative wound infections (except for circumcision). 
o Findings of abscess, pustule, boil with or without drainage 




RISK FACTORS FOR LATE ONSET SEPSIS 
Neonatal • Birthweight 
• Gestational age 
• Prior antibiotic use 
• Indwelling devices 
• Central lines 
• Endotracheal tubes 
• VP shunts 
• Urinary devices 
  
Local/Community • Endemic microbiology (MRSA, Candida prevlance) 
• Feeding practices 
• Bundled practices (ie, CLABSI reduction bundles, feeding 
protocols) 
 







• THOROUGH PHYSICAL EXAM INCLDUING DETAILED SKIN EXAM 
 
LABORATORY SCREENING -All PATIENTS 
• Blood culture should have a minimum volume of 1 ml of blood for infants <750g, 1.5ml 
for ≥750g. 2ml is preferred (strong recommendation, moderate quality evidence) 
o  Ideally, 2 blood cultures should be sent from 2 separate blood draws collected on 
the same calendar day, from 2 separate sites (strong recommendation, moderate 
quality evidence) 
o Central line if present and peripheral or 2 peripherals (weak recommendation, 
low quality evidence) 
• This is particularly important if the infant has a central line to 
differentiate contamination versus infection by commensal 
organisms such as CONS. 
• In all cases a sterile urine culture should be obtained by catheterization or supra-pubic 
aspiration (strong recommendation, moderate quality evidence) 
o Bagged urine cultures should not be performed but may be sent for urinalysis (no 
recommendation) 
• Lumbar puncture (LP) is recommended prior to initiation of antibiotics if the infant is 
able to tolerate procedure (strong recommendation, moderate quality evidence) 
o Meningitis may be difficult to diagnose due to the challenges of performing an 
LP, with results often confounded by blood.  





o  Leukopenia (WBC count <5 x 103/ul) 
o Immature-Total neutrophils ratio >0.27 
o Thrombocytopenia <100 x 103/ul) 
o Absolute neutrophil count < 1500 cell/mm3 
• Consider liver function tests (no recommendation) 
• Chest and abdominal radiographs as appropriate based on localizing signs (no 
recommendation) 
• Imaging of bony structure underlying a skin and soft tissue infection (weak 
recommendation, low quality evidence) 
• Respiratory viral PCR testing, as well as COVID-19 testing should be performed in 
infants with new onset apnea or respiratory failure (weak recommendation, low quality 
evidence) 
 
LABORATORY SCREENING -ADDITIONAL CONSIDERATIONS 
• Consider HSV testing in infants ≤21 days with unexplained hepatitis, skin vesicles or 
progressive illness despite antibiotic therapy (strong recommendation, moderate 
quality evidence) 
o Serum HSV PCR, CSF HSV PCR, surface PCRs (mucous membrane, skin, rectal) 
• Consider CMV testing in infants with thrombocytopenia and elevated direct bilirubin, 
especially if breast fed (strong recommendation, moderate quality evidence) 
o Urine CMV PCR 
• Isolated skin infections in other well appearing infants may have an evaluation limited to 





recommendations made to balance between desirable and undesirable outcomes: 
pain and invasiveness of procedures, need to minimize blood sampling, use of testing 
resources, use of overly broad spectrum antibiotics) 
• Abdominal and renal sonogram are indicated if there is a concern for invasive fungal 
infection (weak recommendation, low quality evidence) 
• Tracheal cultures should not be performed in infants who are not intubated and should be 
interpreted with caution (strong recommendation, moderate quality evidence) 
 
EMPIRIC TREATMENT 
• Sepsis UTI, VAP and skin infections without concern for meningitis: 
o  Oxacillin and amikacin are first line agents, regardless of central line status 
(strong recommendation, moderate quality evidence- large cohort data) 
• Infants with a history of MRSA colonization or prior infection 
o Vancomycin and amikacin (strong recommendation, moderate quality 
evidence) 
• Sepsis with concern for meningitis (strong recommendation, low quality evidence- 
Good Practice Statement) 
o Oxacillin, amikacin and add ceftazidime (vancomycin if history of MRSA 
colonization/infection) 
• NEC: Treatment of NEC includes broad-spectrum antimicrobials; however, there is 
no data supporting a specific, superior antibiotic choice 
o Ampicillin, amikacin and metronidazole are combination first line agents (weak 





o Piperacillin/Tazobactam (+/- vancomycin) may be used for severely ill infants or 
those with a history of Pseudomonas species (weak recommendation, low 
quality evidence) 
• Infants with risk factors for invasive fungal infection such as a history or prior 
colonization (thrush, candida diaper rash), history of long-term antibiotic, steroids or anti-
acid therapy and /or severe hemodynamic instability 
o  Add Amphotericin B deoxycholate, 1 mg/kg q24h (strong recommendation, 
moderate quality evidence – IDSA guidelines) 
o Fluconazole prophylaxis, 6 mg/kg twice weekly be considered in infants <1000g 
being treated with >72h of continuous antibiotic therapy, on antibiotic therapy for 
culture proven sepsis or NEC or receiving a course of systemic steroids for lung 
disease (strong recommendation, high quality evidence- Multicenter clinical 
trial data, IDSA guidelines) 
o Therapy should be limited to 48 hours from initiation of antimicrobials is if 
cultures are negative, unless candidemia or infection with a fastidious organism is 
suspected (strong recommendation, moderate quality evidence – large cohort 
data) 
• Consult ID if the infant has a known multi-drug resistant gram negative, VRE or other 
significant infectious disease history that may influence empiric therapy 
• Consult ID if there is concern for meningitis  
 





1. Repeat blood culture as soon as the first culture is known to be positive (strong 
recommendation, weak quality evidence - Good Practice Statements) 
2. Lumbar puncture for all positive blood cultures except coagulase negative staphylococci, 
if not already performed (strong recommendation, weak quality evidence - Good 
Practice Statements) 
3. Remove central line unless access is critically needed (ie, inotropic support) (strong 
recommendation, moderate quality evidence) 
 
TARGETED TREATMENT* 
4. Uncomplicated Methicillin susceptible Staphylococcus aureus (MSSA) bacteremia: 14 
days of oxacillin counting from the day of the first negative blood culture (strong 
recommendation, weak quality evidence) 
5. CONS bacteremia: 7 days of vancomycin counting from the day of the first negative 
blood culture (strong recommendation, weak quality evidence) 
6. Uncomplicated urinary tract infection: 7 days of therapy. No test of cure necessary. Oral 
therapy can be considered in the infant can absorb enteral antibiotics and if the organism 
is sensitive to an agent with good bioavailability (strong recommendation, weak 
quality evidence) 
• Treatment for NEC should be collaborative with surgical and ID services (no grade) 
o If started, vancomycin should be discontinued if blood culture is negative for 
MRSA or CONS after 48h.  (no grade) 





*The discordant strong recommendation/weak quality of evidence applies to duration of 
therapy, for which no experimental or large or quality cohort data is available. 
 
ID CONSULT REQUIRED FOR: 
• All positive blood cultures for gram negative organisms, GBS, MRSA and fungal species 
• >2 positive blood cultures during an episode of sepsis in infants evaluated for late onset 
sepsis  
• Complicated or disseminated infection: 
o Endocarditis, osteomyelitis, pyelonephritis, intra-abdominal abscesses 
• All positive CSF cultures  
• Concern for HSV 
• Continuation of antibiotics beyond 72h in a patient with negative cultures 
 
 
Appendix: Drug dosages 
Oxacillin dosing is 50mg/kg/dose; interval is based on post menstrual age (PMA, corrected 
gestational age) and day of life 
PMA Day of Life Interval (hours) 












≥45 weeks ALL Q6h 
 
Gentamicin Dosing- Based on Post menstrual age (corrected gestational age) 




















≥35 weeks ALL 4mg/kg Q24h 
 
Gentamicin levels should not be drawn in infants in whom antibiotics are not going to be 
continued beyond 72h unless there is high degree of concern for renal dysfunction 
 
Ceftazidime: Meningitis dosing, all PMAs: 
DOL 0-7 days: 50 mg/kg q12h 
DOL >7 days: 50 mg/kg q8h 
 
Vancomycin dosing is 15mg/kg/dose; interval is based on post menstrual age (PMA, corrected 
gestational age) and day of life 
PMA Day of Life Interval (hours) 












≥45 weeks ALL Q6h 
Vancomycin trough should be done prior to the 4th dose 
 
Piperacillin/Tazobactam dosing is 100mg/kg/dose (of the piperacillin component; interval is 
based on post menstrual age (PMA, corrected gestational age) and day of life 
PMA Day of Life Interval (hours) 


















Metronidazole: loading dose of 15mg/kg, then start 8-24h later based on interval for PMA 
PMA Dose Interval (hours) 
24-25 weeks 7.5mg/kg Q24h 
26-27 weeks 10mg/kg Q24h 
28-33 weeks 7.5mg/kg Q12h 
34-40 weeks 7.5mg/kg Q8h 
>40 weeks 7.5mg/kg Q6h 
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Appendix F: Latent Class Analysis for Diagnosis of NEC 
A latent class is a variable indicating underlying groups of classes based on observable 
characteristics. Membership in a class is said to be “latent” because it cannot be directly 
observed. Latent class models (LCM) relate a set of observed variables to a set of latent 
variables, whereby a class is characterized by a pattern of conditional probabilities that indicate 
the chance that variables take on certain values. Latent class analysis (LCA) is used to find 
classes in multivariate categorical data. A simple two-latent class model has been used to 
estimate indicator accuracy in the diagnosis of disease in the absence of “gold standard” testing 
[132]. In these cases, the true disease status of an individual can be considered as a dichotomous 
latent variable with two categories: diseased or not diseased. Given a set of predictors (i.e., 
clinical signs, symptoms, lab tests) associated with disease but assumed to conditionally 
independent of each other, a 2-class LCA model can be fit and yield estimates of the latent 
prevalence of the disease and the conditional probabilities of a disease status from the pattern of 
responses, as well as sensitivity, specificity and positive predictive value [133, 134, 176].  The 
underlying assumption is that solving a LCA will create latent classes within which there is no 
longer any association of one symptom with another, as the class is the disease which causes 
their association. Controlling for this latent disease status reduces the correlation between 
indicators to zero. 
A formative 2-class LCM to predict and subsequently extract the index latent variable, a 
diagnosis of NEC yes/no in the PHIS dataset at a specific point in time during the infant’s 
hospital admission was created. This model follows the framework shown if Figure 1. 






Figure 1: Schematic diagram of a 2-class LCM, where the Composite Factors represent NEC 
(yes or no), and Y1-Y6 represent predictor variables, zeta the error term. Adapted from Jarvis, 
Mackenzie and Podsakoff, 2005[135] 
 
 
Latent Class Models: 
In typical LCA, a “scale” is formed from a set of items assumed to be reflective measures of the 
latent variable; scores on items in the scale are driven by the latent construct, and analysis seeks 
to reconstruct the number of latent classes that are underlying this structure. By performing 
diagnostic test validation, we reverse this assumption: the items (exposures) are formative of the 
latent variable. We presume then that true disease status can be considered as a dichotomous 
latent variable with only two classes/categories, diseased and not diseased, and that any 
correlation between the exposures will be totally explained by these two classes. 
Mechanics of the Model: 
Population: 
Data were requested on patients admitted between January 1, 2009 and December 31, 2019 who 





II, III, and not otherwise specified (NOS)  and who were <33 weeks gestational age and/or less 
than 1750 grams at birth were included to capture the most certain diagnosis of NEC. 
 
Outcome measure: 
ICD-9 and -10 codes for the outcome, NEC, that were included in the analysis are shown table 1.  
 




Description Diagnostic Correlate 
ICD- 9: P777.52 
ICD-10: P77.2 
Stage II necrotizing enterocolitis in 
newborn 
• Necrotizing enterocolitis with 
pneumatosis, without perforation 
 
Bell’s Stage IIa or B, 
Stage IIIa 
NHSN Medical or 
Surgical NEC 
ICD- 9: P777.53 
ICD-10: P77.3 
Stage III necrotizing enterocolitis in 
newborn 
• Necrotizing enterocolitis with 
perforation 
• Necrotizing enterocolitis with 
pneumatosis and perforation 
Bell’s Stage IIIb 
NHSN Medical or 
Surgical NEC 
ICD- 9: P777.50 
ICD-10: P77.9 






Mandatory exposure variables with overlapping time periods were the administration of broad-
spectrum therapy for ≥5 calendar days in duration AND abdominal radiographs performed for ≥3 
consecutive days during antibiotic course AND patient receipt of ≥3 days of TPN. Broad 





cefazolin, oxacillin, nafcillin, vancomycin, penicillin, ampicillin, clindamycin, gentamicin, 
tobramycin, or amikacin, or oral or topical therapy.  
 
I adjudicated the exposure variables and diagnosis of NEC in patients from 2 sites (Columbia 
Presbyterian and Cornell Medical Center) within PHIS using manual chart review of the medical 
records of infants with an ICD-9 or 10 diagnosis of NEC (N=163). It was manually validated that 
all the infants who had an ICD-9 or 10 diagnosis of NEC did indeed have “NEC at a specific 
time X,” as identified by the 3 exposure variables, except in infants who died within 5 days of 
their diagnosis (N=2). An LCA was run in the “M plus” statistical modeling program. The 3 
mandatory exposure items were modelled in a 2-class analysis. The new latent variable that was 
created indicates class membership in “NEC at a specific time X.”  
This model was a success by technical standards; the new latent variable that was created 
accurately reflected the date of diagnosis of NEC in the PHIS data set; however, this was not 
unexpected as all the patients had the same response pattern except those infants that died; as 
such, the probabilities of belonging to the latent class “NEC at a specific time X” is very high.  
Statistical validation of the model and challenges of LCA modelling: 
As stated above, LCM are typically exploratory, and the number of latent classes are usually not 
held fixed. For our model to be valid, we presume that disease is a dichotomous variable, and 
that patients are homogenous within each latent class.  
Adequate sample size is not well defined for LCA models; in general, each latent class should 
have > 5 members. Based on recent estimates of the PHIS dataset, we estimate that it contains 
approximately 300,000 neonates < 90 days admitted to the NICU and approximately 4000 





correlation between exposures that is not explained solely by disease; this leads to a lower 
“quality” of the items. Ideally, for each person we want probability of class membership to be 
large for one of the classes and small for all the rest, suggesting clear classification into one and 
only one class. Lower quality items make the probability of class membership more difficult to 
discern, making a larger sample size a necessity.   
 
MPlus code for LSV Model: 
 
“Title: LSV for NEC 
Data: file = "C:\Users\19178\Dropbox\lsv csv nec.dat"; 
Variable: names= id AXR ABX5 TPN NEC; 
                  usevariables  = AXR ABX5 TPN; 
                   idvariable = id; 
                  categorical = AXR ABX5 TPN; 
                 missing are .; 
                  classes = nec(2); 
  Analysis: type = mixture; 
              starts = 500 50; 
             stiterations = 50; 
Plot: type = plot3; 
   series = AXR(1) ABX5(2) TPN(3); 
  Savedata: file= lsvnec.dat; 
    save=cprobabilities; 




LSV Model Output 
 
INPUT INSTRUCTIONS 
   Title: 
              LSV for NEC 
          Data: 
                  file = "C:\Users\19178\Dropbox\lsv csv nec.dat"; 
          Variable: names= id AXR ABX5 TPN NEC; 
                  usevariables  = AXR ABX5 TPN; 
                   idvariable = id; 





                 missing are .; 
                  classes = nec(2); 
  Analysis: type = mixture; 
             starts = 500 50; 
             stiterations = 50; 
          Plot: 
                  type = plot3; 
                  series = AXR(1) ABX5(2) TPN(3); 
  Savedata: file= lsvnec.dat; 
            save=cprobabilities; 
  output:  TECH7 TECH10 
 
INPUT READING TERMINATED NORMALLY 
LSV for NEC 
SUMMARY OF ANALYSIS 
 
Number of groups                                                 1 
Number of observations                                         163 
Number of dependent variables                                    3 
Number of independent variables                                  0 
Number of continuous latent variables                            0 
Number of categorical latent variables                           1 
Observed dependent variables 
  Binary and ordered categorical (ordinal) 
   AXR         ABX5        TPN 
Categorical latent variables 
   NEC 
Variables with special functions 
 ID variable           ID 
 
Estimator                                                      MLR 
Information matrix                                        OBSERVED 
Optimization Specifications for the Quasi-Newton Algorithm for 
Continuous Outcomes 
  Maximum number of iterations                                 100 
  Convergence criterion                                  0.100D-05 
Optimization Specifications for the EM Algorithm 
  Maximum number of iterations                                 500 
  Convergence criteria 
    Loglikelihood change                                 0.100D-06 
    Relative loglikelihood change                        0.100D-06 
    Derivative                                           0.100D-05 





Categorical Latent variables 
  Number of M step iterations                                    1 
  M step convergence criterion                           0.100D-05 
  Basis for M step termination                           ITERATION 
Optimization Specifications for the M step of the EM Algorithm for 
Censored, Binary or Ordered Categorical (Ordinal), Unordered 
Categorical (Nominal) and Count Outcomes 
  Number of M step iterations                                    1 
  M step convergence criterion                           0.100D-05 
  Basis for M step termination                           ITERATION 
  Maximum value for logit thresholds                            15 
  Minimum value for logit thresholds                           -15 
  Minimum expected cell size for chi-square              0.100D-01 
Maximum number of iterations for H1                           2000 
Convergence criterion for H1                             0.100D-03 
Optimization algorithm                                         EMA 
Random Starts Specifications 
  Number of initial stage random starts                        500 
  Number of final stage optimizations                           50 
  Number of initial stage iterations                            50 
  Initial stage convergence criterion                    0.100D+01 
  Random starts scale                                    0.500D+01 
  Random seed for generating random starts                       0 
Link                                                         LOGIT 
Input data file(s) 
  C:\Users\19178\Dropbox\lsv csv nec.dat 
Input data format  FREE 
 
SUMMARY OF DATA 
     Number of missing data patterns             1 
     Number of y missing data patterns           0 
     Number of u missing data patterns           1 
 
COVARIANCE COVERAGE OF DATA 
Minimum covariance coverage value   0.100 
 
UNIVARIATE PROPORTIONS AND COUNTS FOR CATEGORICAL VARIABLES 
    AXR 
      Category 1    0.012            2.000 
      Category 2    0.988          161.000 
    ABX5 
      Category 1    0.012            2.000 





    TPN 
      Category 1    0.012            2.000 
      Category 2    0.988          161.000 
 
RANDOM STARTS RESULTS RANKED FROM THE BEST TO THE WORST LOGLIKELIHOOD VALUES 
Final stage loglikelihood values at local maxima, seeds, and initial stage start numbers: 
             -10.789  533738           11 
             -10.789  622860           259 
             -10.789  313407           132 
             -10.789  232559           136 
             -10.789  576726           280 
             -10.789  597614           284 
             -10.789  824126           287 
             -10.789  260601           36 
             -10.789  76337            76 
             -10.789  246261           38 
             -10.789  383986           159 
             -10.789  900268           327 
             -10.789  669634           335 
             -10.789  602797           336 
             -10.789  286735           175 
             -10.789  476498           179 
             -10.789  349562           359 
             -10.789  717754           180 
             -10.789  801717           364 
             -10.789  407108           366 
             -10.789  887676           22 
             -10.789  402224           91 
             -10.789  836066           372 
             -10.789  182524           373 
             -10.789  871851           257 
             -10.789  1548             384 
             -10.789  570782           193 
             -10.789  395754           388 
             -10.789  415502           194 
             -10.789  50887            389 
             -10.789  714997           399 
             -10.789  97158            205 
             -10.789  85734            411 
             -10.789  85462            51 
             -10.789  292884           103 
             -10.789  399508           415 





             -10.789  853195           431 
             -10.789  39136            226 
             -10.789  359578           458 
             -10.789  349360           464 
             -10.789  751054           117 
             -10.789  301180           236 
             -10.789  787985           482 
             -10.789  443917           60 
             -10.789  252949           487 
             -10.789  432148           30 
             -10.789  123985           248 
             -10.789  715561           125 
             -10.789  340112           126 
 
THE BEST LOGLIKELIHOOD VALUE HAS BEEN REPLICATED.  RERUN WITH AT LEAST TWICE THE 
RANDOM STARTS TO CHECK THAT THE BEST LOGLIKELIHOOD IS STILL OBTAINED AND REPLICATED. 
 
IN THE OPTIMIZATION, ONE OR MORE LOGIT THRESHOLDS APPROACHED EXTREME VALUES OF -15.000 
AND 15.000 AND WERE FIXED TO STABILIZE MODEL ESTIMATION.  THESE   VALUES IMPLY PROBABILITIES 
OF 0 AND 1.  IN THE MODEL RESULTS SECTION, THESE   PARAMETERS HAVE 0 STANDARD ERRORS AND 
999 IN THE Z-SCORE AND P-VALUE COLUMNS THE MODEL ESTIMATION TERMINATED NORMALLY 
 
MODEL FIT INFORMATION 
Number of Free Parameters                        7 
Loglikelihood 
          H0 Value                         -10.789 
          H0 Scaling Correction Factor      1.0000 




          Akaike (AIC)                      35.578 
          Bayesian (BIC)                    57.234 
          Sample-Size Adjusted BIC          35.073 
            (n* = (n + 2) / 24) 
 
Chi-Square Test of Model Fit for the Binary and Ordered Categorical (Ordinal) Outcomes 
          Pearson Chi-Square 
          Value                              0.000 
          Degrees of Freedom                     0 
          P-Value                           1.0000 
 





          Value                              0.000 
          Degrees of Freedom                     0 
          P-Value                           1.0000 
 
FINAL CLASS COUNTS AND PROPORTIONS FOR THE LATENT CLASSES BASED ON THE ESTIMATED MODEL 
    Latent Classes 
       1        161.00000          0.98773 
       2          2.00000          0.01227 
 
FINAL CLASS COUNTS AND PROPORTIONS FOR THE LATENT CLASSES BASED ON ESTIMATED POSTERIOR 
PROBABILITIES 
  Latent Classes 
       1        161.00000          0.98773 
       2          2.00000          0.01227 
 
FINAL CLASS COUNTS AND PROPORTIONS FOR THE LATENT CLASSES BASED ON THEIR MOST LIKELY 
LATENT CLASS MEMBERSHIP 
Class Counts and Proportions 
    Latent  Classes 
       1              161          0.98773 
       2                2          0.01227 
 
CLASSIFICATION QUALITY 
Entropy                         1.000 
Classification Probabilities for the Most Likely Latent Class Membership (Column) by Latent Class (Row) 
           1           2 
    1   1.000    0.000 
    2   0.000    1.000 
 
Logits for the Classification Probabilities for the Most Likely Latent Class Membership (Column) by Latent 
Class (Row) 
              1             2 
    1     13.816    0.000 




                                                    Two-Tailed 
                    Estimate       S.E.  Est./S.E.    P-Value 
 
Latent Class 1 
Thresholds 





    ABX5$1           -15.000      0.000    999.000    999.000 
    TPN$1            -15.000      0.000    999.000    999.000 
 
Latent Class 2 
 Thresholds 
    AXR$1             15.000      0.000    999.000    999.000 
    ABX5$1            15.000      0.000    999.000    999.000 
    TPN$1             15.000      0.000    999.000    999.000 
 
Categorical Latent Variables 
 Means 
    NEC#1              4.388      0.711      6.168      0.000 
 
RESULTS IN PROBABILITY SCALE 
 
Latent Class 1 
 AXR 
    Category 1         0.000      0.000      0.000      1.000 
    Category 2         1.000      0.000      0.000      1.000 
 ABX5 
    Category 1         0.000      0.000      0.000      1.000 
    Category 2         1.000      0.000      0.000      1.000 
 TPN 
    Category 1         0.000      0.000      0.000      1.000 
    Category 2         1.000      0.000      0.000      1.000 
 
Latent Class 2 
 AXR 
    Category 1         1.000      0.000      0.000      1.000 
    Category 2         0.000      0.000      0.000      1.000 
 ABX5 
    Category 1         1.000      0.000      0.000      1.000 
    Category 2         0.000      0.000      0.000      1.000 
 TPN 
    Category 1         1.000      0.000      0.000      1.000 
    Category 2         0.000      0.000      0.000      1.000 
 
LATENT CLASS ODDS RATIO RESULTS 
                                         (Est. - 1) Two-Tailed 
                    Estimate       S.E.     / S.E.    P-Value 
 






    Category > 1   *********      0.000    999.000    999.000 
 ABX5 
    Category > 1   *********      0.000    999.000    999.000 
 TPN 
    Category > 1   *********      0.000    999.000    999.000 
 
QUALITY OF NUMERICAL RESULTS 
  Condition Number for the Information Matrix              0.506E+00 
     (ratio of smallest to largest eigenvalue)” 
 
